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1. INTRODUCTION 
Our immune system is composed of different specialized molecules, cells, 
tissues and organs, evolved to defend us against foreign substances and 
diseases. Simultaneously identifying foreign molecules the immune system 
must be sophisticated enough to differentiate between hostʼs cells and remain 
tolerant to its components. Tolerance mechanisms are obligatory because our 
immune system randomly produces diversity of antigen-specific receptors, 
some of which might be self-reactive; and tolerance prevents harmful reactions 
against the bodyʼs own tissues. Failure of the immunological tolerance against 
self may lead to autoimmune diseases. The etiology of many autoimmune 
diseases is genetically complex and many genes act in concert to induce auto-
immunity, and only rarely mutations in single gene cause autoimmune disease. 
Recently it was found that mutations in a AIRE (Autoimmune regulator) 
gene are sufficient to elicit a rare multiorgan autoimmune disease known as 
APECED (Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dys-
trophy) syndrome, which is a good monogenic model to study development of 
tolerance towards self components and autoimmunity. APECED is charac-
terized by a loss of immunological self-tolerance towards several endocrine 
organs including parathyroid and adrenal glands. AIRE is mainly expressed in 
medullary thymic epithelial cells (mTECs), where it directs the promiscuous 
(also known as open) gene expression of peripheral tissue-specific antigens by 
presenting them to developing thymocytes and thereby driving the negative 
selection of autoreactive T cells. Presentation of self-proteins via MHC on 
mTECs is necessary for central tolerance establishment. The additional involve-
ment of thymic chemokines in the establishment of central tolerance has been 
proposed but the mechanisms are not clear. In the context of the tissue specific 
expression, it has been proposed that AIRE might be regulated on the level of 
epigenetic modifications including CpG methylation, chromatin modification, 
but the exact mechanisms remain still enigmatic. 
Current thesis focuses on the role of mouse Aire gene in peripheral tissue-
specific antigen and chemokine expression; and human AIRE promoter analysis 
in thymic epithelial cell populations, thymomas and normal peripheral tissue 
samples in order to gain insight, whether AIRE mTEC restricted expression is 
dependent on genomic methylation. 
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2. REVIEW OF LITERATURE 
2.1. Immune system and tolerance 
The immune system has developed to protect host from invading extracellular and 
intracellular pathogens. The immune tolerance is a property of the immune system 
not to attack specific antigens. Antigens are defined as molecules that are 
recognized by lymphocyte receptors on B and T cells. The tolerance can be devided 
into two types: central tolerance and peripheral tolerance. Central tolerance is 
related to lymphocyte development and operates mainly in the thymus and it 
eliminates majority of potentially dangerous T cells [1]. Peripheral tolerance 
develops outside the thymus and controls self-reactive T cells that have escaped 
central tolerance in the thymus [2]. For B cells, the central tolerance occurs in the 
bone marrow (central tolerance) and in periphery (peripheral tolerance), and B cells 
do not react against majority of antigens without T cells help [3]. 
 
2.1.1. Thymus, homing chemokines and their function  
in T cell maturation 
Thymus is an essential primary lymphoid organ that develops from the third 
pharyngeal pouch of the anterior gut and supports the differentiation and selection 
of T cells and establishment of self-tolerance [4]. Thymus is bilobed organ in the 
thoracic cavity overlying the heart and major blood vessels. The two distinct lobes 
are joined by a connective tissue isthmus. Both lobes are organized into lobules 
subdivided from each other by connective tissue trabeculae. In addition to thoracic 
thymus, a functional cervical thymus in mice has been reported [5]. The thymus is 
proportionally the largest during infancy and subsequently involutes, which is 
defined as a decrease in the size and weight with progressing age. Involution starts 
at puberty and during this process the epithelial compartment atrophies and is 
replaced by abundant adipose tissue and lymphocytes [6]. 
Thymus is organized into outer cortex of immature T cells and inner medulla 
of more mature T cells, implying a differentiation gradient from cortex to me-
dulla. The cortex consists mostly of immature thymocytes and in smaller 
numbers, of epithelial cells and macrophages. The medulla contains predomi-
nantly of epithelial cells and mature thymocytes, Hassallʼs corpuscles, macro-
phages and dendritic cells (DC) but also fibroblasts [4]. The epithelial cells of 
the Hassallʼs corpuscles produce thymic stromal lymphopoietin (TSLP), which 
activates maturation of thymic DCs and that in turn induces differentiation of 
regulatory T cells (Tregs) in the medulla of human thymus [7]. TSLP-activated 
DC secrete chemokines CCL22 and CCL17 [8], which are important in guiding 
the traffic of developing immature T cells to the medulla [9, 10]. Hassallʼs 
corpuscles may play significant role in DC mediated central tolerance. 
Lympho-stromal crosstalk (interactions between T cells and nonhematopoietic 
cells) in the thymus has a critical role in the regulation of T cell development and 
selection. During the T cell development in the thymus the proper dynamic 
relocation of T cells at the right places and in the right order is needed, and also 
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close and remote crosstalk between the developing T cells and thymic stromal cells 
is obligatory. These processes include: first, the entrance of developing lympho-
cytes into the thymus; second, the generation of CD4+CD8+ double-positive (DP) 
thymocytes at the outer cortex of the thymus; third, the positive and negative 
selection of DP in the cortex; forth, interactions of mTECs with positively selected 
thymocytes for final development and central tolerance; fifth, export of mature 
thymocytes [11]. Thymic stromal cells produce chemokines as a homing cross-talk 
signal, which guides migration of developing thymocytes through individual 
microenvironments in the thymus, and developing thymocytes express different 
chemokine receptors for chemotactic guidance [11]. 
Chemokines are a family of small chemotactic cytokines, or proteins secreted by 
cells. The major role of chemokines is to induce directed chemotaxis in nearby 
responsive cells. They share structural characteristics such as small size (approx. 
~8–14 kDa) and by the spacing of 4 conserved cysteins forming two essential 
disulphide bonds (Cys1-Cys3 and Cys2-Cys4). In CC-chemokine family, the first 2 
cysteines are adjacent, whereas in CXC family they are separated by a non-
conserved residue [12, 13]. Many chemokines are constitutively expressed in the 
thymus and in lymph nodes and spleen, including CCL17 [14], CCL19 [15–17], 
CCL21 [15, 18], CCL22 [19, 20] and CCL25 [21]. Their thymic expression implies 
that they play role in thymocyte migration and thymic development. 
Entry of lymphoid progenitor cells into the thymus occurs as early as embryonic 
day 11.5 (E11.5) in mice and during the eighth week of gestation in humans [22, 
23]. The entrance occurs in waves during embryogenesis and in adulthood [24]. 
The thymus is seeded at least by two different pathways: the vasculature-
independent pathway, which probably occurs during the early stage of embryonic 
development before vascularization and is regulated by chemotactic attraction, and 
the vasculature-dependent pathway, which probably takes place in the late stage of 
emryogenesis and postnatally after vascularization. Chemokines, CCL21 and 
CCL25, are partially involved in the vasculature-independent colonization of early 
stage of fetal thymus. In postnatal thymus, the lymphoid progenitor cells enter the 
thymus through the area around the cortico-medullary junction [11]. The chemo-
kine receptors CCR9, CCR7 and CXCR4 cooperatively regulate homing of 
hematopoietic progenitors to the embryonic mouse thymus [25], whereas in adult 
thymus CCR7 and CCR9 recruit hematopoietic progenitors [26]. 
After their entrance to thymus, the lymphoid progenitors start to develop into 
CD4-CD8- double negative (DN) cells and relocate to the subcapsular zone in the 
cortex (Figure 1). Chemokine receptors CXCR4, CCR7 and CCR9 have been sug-
gested to guide movement of immature thymocytes. Along with this movement im-
mature DN thymocytes drive thymic stromal differentiation and cause the develop-
ment of the cortical-epithelial environment. On the route to the subcapsular zone, 
the DN thymocytes rearrange T-cell receptor (TCR) gene segments, move inwards 
cortex and develop to CD4+CD8+ double positive (DP) cells. The cortical DP 
thymocytes have TCRs with a broad repertoire of antigen specificities. Since the ge-
neration of TCRs is highly random, a large number of different TCRs are made and 
thymocytes that make either nonfunctional receptor or recognise self-proteins die.  
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Figure 1. Traffic of thymocytes inside of the thymic compartments. In the postnatal 
thymus, circulating developing lymphocytes migrate into the thymus through the blood 
vessels in corticomedullary junction and migrate outwards to the capsule by chemokine 
signals through CXCR4 and CCR7 receptors. Further outward migration to the sub-
capsular region is mediated by CCR9 signals. Positively selected CD4+CD8+ DP diffe-
rentiate into CD4+ and CD8+ T cells, and express CCR7 receptors, through which they 
are attracted to the medulla. In the medulla, SP thymocytes are further selected and 
tissue-specific-antigen-reactive T cells are deleted. Mature SP thymocytes are migrating 
back to the circulation. Modified from [11]. 
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The functional and self-tolerant T-cell repertoire is achieved by presentation of 
different self-peptides bound to the major histocompatibility complex (MHC) 
molecules that are expressed by antigen-presenting cells (APCs). T cells interact via 
TCR with peptide-MHC complexes expressed by cTECs and DCs in the cortex. 
After T cells recognize peptide-MHC complex at intermediate avidity interaction, 
DP thymocytes receive signals for survival and differentiation into CD4+CD8- or 
CD4-CD8+ single positive (SP) thymocytes. This process, which is known as 
positive selection, ensures the elimination of T cells with nonfunctional receptor. T 
cells with very high or without receptor affinities towards self MHC undergo 
apoptosis and die in the cortex. Only 3–5% thymocytes survive positive selection. 
Positively selected thymocytes are induced to express CCR7 and are attracted to its 
ligands, CCL19 and CCL21, which are produced by mTECs and attracted to 
medulla via CCR7-mediated chemotaxis. Tolerance to self antigens is achieved in 
medulla, where self-reactive thymocytes that have passed positive selection in 
cortex are additionally screened. Thymocytes with TCRs that bind peptide-MHC 
complex with high avidity undergo apoptosis and are deleted. This process is 
known as negative selection and prevents emigration of self reactive thymocytes to 
periphery. Although the negative selection is highly efficient in eliminating the vast 
majority of self reactive thymocytes, some cells still escape from thymus to the 
periphery and their activation can lead to autoimmune diseases [11, 27]. 
In medulla, many different cell types present self-antigens to developing T 
cells (Figure 2). Thymic DCs are the most efficient APCs in thymus and bring 
peripheral antigens into the thymus [28, 29] and cross-present antigens to both 
CD4+ and CD8+ T cells [30]. mTECs are unique cell type that express wide range 
of tissue specific antigens (TSAs) that are usually expressed only in specific 
tissues [31], which leads to the elimination of self-reactive thymocytes [32, 33] 
and to presentation of these antigens to CD4+ and CD8+ medullary thymocytes 
[27]. During mTEC differentiation AIRE (Autoimmune Regulator) protein in-
duces apoptosis and it is suggested that apoptosis is induced via direct induction 
of apoptotic program or indirectly via TSA upregulation that overload protein 
synthesis machinery to provoke death through endoplasmatic reticulum stress 
[34]. Thymic epithelial cells are capable to transfer membrane material, including 
MHC molecules, between epithelial cells and transfer MHC class I (MHCI) and 
MHC class II (MHCII) to DC but not reciprocally [35, 36]. mTECs, in addition to 
being an antigen reservoir, also function as APCs by directly presenting antigens 
to developing T cells [37]. The promiscuous (also known as open) gene ex-
pression of TSAs broadens the scope of self-antigens presented to developing 
thymocytes to facilitate central tolerance towards self [27]. 
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Figure 2. Self-antigens presetation to developing T cells. In mTECs, AIRE induces the 
expression of a wide repertoire of TSAs, which are processed to peptides and then 
presented on cell surface through MHC/HLA molecules. mTECs die by apoptosis after 
the induction of AIRE and TSAs, and apoptotic mTECs can be engulfed by DCs. 
Mature thymocytes translocate to medulla scanning for presented MHC:TSA complexes 
on mTECs or DCs and if their TCRs recognise presented complex with appropriate 
affinity, they will be deleted from the repertoire. 
 
2.1.2. Autoimmunity 
Autoimmunity is the failure of an organism to recognise its components as self, 
which results immune recognition and reaction against its own cells and tissues. 
Autoimmunity is associated with many diseases, which can be either organ-
specific or with systemic distribution meaning that the response is primarily 
against particular organ specific antigens or against widespread antigens. 
Altogether 3–5% of population is affected by autoimmune diseases and women 
are affected to greater extent than men (sex ratio 3:1) [38]. The most common 
organ specific autoimmune diseases are Hashimotoʼs throiditis (targeted organ: 
thyroid gland), myasthenia gravis (muscle), pernicious anemia (stomach), 
Addisonʼs disease (adrenal gland), insulin-dependent diabetes mellitus (pancreas). 
In systemic non-organ-specific diseases, such as systemic lupus erythematosus, 
scleroderma and SLE, rheumatoid arthritis, psoriasis, symptoms are often present 
in the skin, joints, kindney and muscle, which can be considerably affected. 
Autoimmune diseases can overlap and one individual may have more than one 
disease. Autoimmune diseases have a complex genetic basis, which means that 
many genes and triggering environmental factors act in concert to elicit auto-
immunity [39, 40]. Autoimmune diseases caused by single-gene defects are very 
rare, but enable to study how defects in the immune system lead to the develop-
ment of autoimmunity. Currently recognized monogenic autoimmune diseases are 
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IPEX (defect in Foxp3 gene) (immunodysregulation polyendocrinopathy entero-
pathy and X-linked inheritance syndrome) (OMIM 304790), ALPS (defect in 
FAS gene) (autoimmune lymphoproliferative syndrome) (OMIM 601859), IL-
2Rα deficiency  (interleukin-2 receptor alpha-chain deficiency) (OMIM 606367) 
and APECED (defect in AIRE gene) (autoimmune polyendocrinopathy candi-
diasis and ectodermal dystrophy) (OMIM 240300) [38]. 
  
2.1.3. APECED 
Autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy 
(APECED), also known as autoimmune polyglandular syndrome type 1 (APS1), 
is a monogenic polyendocrine disease childhood onset and caused by mutations 
in the AIRE gene [41, 42]. Over 60 APECED-associated mutations have been 
reported in AIRE gene and APECED clinical picture varies in severity and in 
the number of disease components [78]. APECED is a rare disease, with high 
frequency among Iranian Jews (1:9000) [43], Sardinians (1:14 400) [44], Finns 
(1:25 000) [45] and Norwegians (1:90 000) [46]. The three major clinical mani-
festations associated with APECED classically involve hypoparathyroidism, 
chronic mucocutaneous candidiasis and primary adrenocortical insufficiency 
(Addisonʼs disease), which vary in scope and timing. Two manifestations out of 
3 are needed to fulfil the clinical diagnostic criteria. In addition, other auto-
immune diseases might be present, such as hypothyroidism, primary hypogona-
dism, insulin-dependent diabetes mellitus, chronic active hepatitis, juvenile-
onset pernicious anemia, vitiligo, alopecia and ectodermal dysplasia. The 
presence of autoantibodies emphasizes the role of autoimmunity in the patho-
genesis of APECED. The autoantibodies are against several defined antigens, 
most often tissue-specific enzymes in the affected tissue. Nevertheless, tissue 
destruction is mediated by autoreactive T cells [47]. Also, the patients have 
autoantibodies against cytokines such as IL-17A and IL-22, which might 
explain the development of chronic mucocutaneous candidiasis [48, 49]. The 
early finding of high titer autoantibodies (interferon-ω and –α2) has created a 
useful diagnostic test for APECED diagnosis [50]. APECED patients have Treg 
defect, which is associated with loss of naive precurors [51], although in Aire 
deficient mouse model peripheral Treg cells seem normal [52]. Functional 
Tregs are the final checkpoint in the pathogenetic events and defect in Tregs can 
guide to impaired control of the pathological processes leading to APECED.  
 
 
2.2. AIRE and central tolerance 
2.2.1. AIRE 
The human AIRE gene locates on chromosome 21q22.3 with 14 exons spanning 
11.9 kb of genomic DNA, the encoded protein consists of 545 amino acid 
residues and the molecular weight is 57.7 kDa [41, 42]. The mouse Aire gene 
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has also 14 exons but spans over 13kb on chromosome 10 and encodes protein 
of 552 amino acids. Mouse and human AIRE share 71% similarity at the protein 
level [53–55]. AIRE contains several structural domains intrinsic for transcrip-
tional regulators and chromatin-binding proteins (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Domain structure of the AIRE protein. AIRE protein contains several do-
mains and functional elements such as CARD, NLS, SAND, PHD, PRR, LXXLL 
(indicated in different colours). Functions of AIRE are shown with arrows pointing to 
the respective domain. Modified from [56]. 
 
 
The N-terminal region of AIRE gene contains caspase-recruitment domain 
(CARD) [57], overlaps with a homogenously staining region (HSR) domain, 
which is responsible for dimerization of the protein [58] or in interaction with 
other transcriptional control proteins, like CBP [57]. CARD is followed by 
SAND domain, termed by Sp100, AIRE, NucP41/75 and DEAF-1, responsible 
for the DNA-binding [59]. SAND domain is found in a number of nuclear 
proteins, many of which function in chromatin-dependent transcriptional 
control. The DNA-binding properties are centred around the conserved KDWK 
core motif [60]. Two plant homeodomain (PHD) zinc fingers are also found in 
AIRE and are separated by proline rich region (PRR). Mutations in PHD fingers 
reduce the transcriptional activation capacity of the AIRE protein [61–64].The 
PHD1 finger of the AIRE protein has been suggested to function as an E3 
ubiquitin ligase [65], albeit subsequent study argues against [66]. C-terminal 30 
amino acids, including the proline-rich PXXPXP motif, are important for 
transactivation [63]. Both the N- and C-terminal regions of the protein contain 
nuclear hormone binding LXXLL motifs (L is leucine and X any amino acid) 
[42]. AIRE has two functional nuclear localization signals (NLS), the consensus 
NLS of the N-terminus and another NLS in the C-terminus, whereas the nuclear 
export signal (NES) resides in the N-terminal HSR domain of AIRE [58]. 
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2.2.2. The trancriptional control of AIRE gene 
During the characterization of human AIRE gene, a putative promoter with a 
TATA box and a CpG island was discovered, and a GC box upstream of first 
exon was found [41]. Altogether, five GC boxes are located in human AIRE but 
none in the mouse promoter sequence. Based on computational analysis, within 
the 600 bp upstream of the ATG translation site several conserved transcription 
factor binding sites were discovered for thymus specific (Ets-1 and Gfi1) and 
hematopoietic transcription factors [54]. Also, it included sites for essential 
components of the basal transcriptional complex such as AP-4, an inverted 
CCAAT box and a typical TATA box [54]. 
Several years later, Murumägi et al. carried out studies on characterization of 
regulatory elements and methylation pattern of the AIRE promoter. They 
identified that human AIRE gene promoter contains indeed a CpG island, a 
typical TATA box and functional binding sites for positive cis-regulatory 
elements (for minimal promoter activity), such as the ubiquitously expressed 
transcription factors specificity protein 1 (Sp1), nuclear factor Y (NF-Y), 
activator protein 1 (AP-1) and E-twenty-six (Ets) family of transcription factors 
[67, 68]. The CpG island is highly hypermethylated in several AIRE-negative 
cell lines such as HeLa, TEC1A3, THP-1, U937 [68]. Furthermore, AIRE ex-
pression was detected in methyltransferase-defective cell line, suggesting the 
regulation of AIRE gene expression via CpG methylation [69]. 
 
2.2.3. AIRE expression pattern 
AIRE is highly expressed in a subpopulation of mTECs within the thymus. In 
addition to thymus, AIRE is expressed at low levels in spleen, lymph node para-
cortex, fetal liver [41, 42, 70, 71], and in ovary and testis [52, 72, 73]. Recently, 
AIRE-expressing cells have been found in human peripheral lymphoid tissues, 
including tonsils and gut-associated lymphoid tissue (GALT) [74]. Extrathymic 
AIRE+ cells show DC morphology [74], which agrees with the previous fin-
dings that AIRE is expressed in peripheral blood monocytes [70, 75] and in 
differentiated DCs [75]. In mice, Aire expression at the early embryo before 
emergence of the three germ cell layers (i.e. before gastrulation at embryonic 
day E6.5) was recently described [76]. Also, Aire was present at the two-cell 
stage, blastocycts and ES cells. In addition, ES cells and induced pluripotent 
stem (iPS) cells of human origin expressed AIRE [76]. 
At the subcellular level, AIRE protein is located in the cell nucleus and in 
nuclear dots resembling promyelocytic leukemia (PML) bodies. Whereas, AIRE 
nuclear bodies localize separate from PML bodies [58, 70]. The function of 
AIRE nuclear bodies is not known. AIRE subcellular location and its structural 
features support its role as a transcriptional activator and involvement in the 
regulation of gene expression [77]. 
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2.2.4. AIRE function in thymus and self-tolerance 
The development of Aire-deficient mouse models for APECED provides new 
hints about AIRE role in immune regulation and the pathogenesis of APECED. 
Similarly to APECED patients, Aire-deficient mice develop lymphocytic 
infiltrations (in retina of eye, salivary gland, stomach, ovary, pancreas, thyroid), 
circulating organ-specific autoantibodies and infertility [52, 79, 80]. Although, 
it has been reported that Aire-deficient mice do not develop the same profile of 
autoantibodies as in the patients with APECED, the finding suggests that AIRE 
might control a different set of genes in mice and in humans [81]. 
AIRE expression is defined to end-stage matured mTECs [34, 82], charac-
terized by high expression levels of MHC class II molecules and costimulatory 
molecules CD80, CD86 and CD40 [71, 83]. mTECs specialize in promiscuous 
expression of hundreds of TSAs, which are intrinsic to different peripheral 
tissues [31]. Conducted gene-expression microarray of mTECs from Aire-
deficient and wild-type (WT) mice revealed, that Aire directs the expression of 
peripheral TSAs. In mTECs, Aire activates the expression of approximately 
200–1200 different genes [52]. The complexity of promiscuous gene expression 
in mTECs is differentiation dependent and increases from immature CD80lo to 
mature CD80hi mTECs [83]. AIRE regulated genes have stochastic expression 
and 1–3% of total mTECs express a particular TSA [84]. Loss of Aire and 
thereby inefficient antigen presentation by mTECs causes failure to negatively 
select organ-specific T cells in the thymus [32, 33]. To date, the significance of 
thymic expression of TSAs has been shown by different studies, which link 
specific thymic TSAs and autoimmune phenotype. And the lack of a single TSA 
in the thymus is suffient to trigger organ-specific autoimmunity [85–87]. 
Clearly, the promiscuous expression driven by Aire is obligatory for proper 
negative selection and protection against autoimmunity. 
 
2.2.5. Thymomas 
Thymomas are histologically diverse neoplasms of thymic epithelial cells and are 
classified according to their architectural features and content of lymphocytes into 
several subtypes [88]. The 2004 World Health Organization (WHO) classification 
divides thymomas into types A, AB, B1, B2 and B3 based on the morphology of 
the neoplastic cells and the relative amount of a non-neoplastic lymphocytic 
component [89]. Stage of their metastatic spread, in addition to complete 
resection, has demonstrated to be the best single prognostic marker for thymoma 
therapy. Approximately over 80% of thymomas are thymopoietic and generate SP 
CD4+ and CD8+ T cells and generation of T cells varies according to the thymoma 
subtype: it is minimal or absent in type A thymomas; it is prominent but scattered 
and relatively inefficient in type AB generating few mature SP T cells; it is 
abundant and almost normal in types B1 and B2; and it is sparse but still normal 
in type B3. The most common autoimmune manifestation in thymoma patients is 
myasthenia gravis (MG), which is found approximately in 10–50% of thymoma 
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patients. Immunohistochemical analysis have shown that the expression of 
MHCII was strongly or moderately reduced in the vast majority of thymomas, but 
regrouping according to presence or lack of MG, demonstrated that MG occurs 
predominantly in thymomas with high MHCII expression levels [90]. About 95% 
of thymomas lack the AIRE and AIRE-dependent antigen expression, which has 
maintained in their remnant thymic tissue and lymph nodes [91]. Only type B1 
thymoma contains AIRE+ mTECs and has a tissue architecture resembling normal 
thymus with the most clear-cut corticomedullary differentiation among 
thymomas, frequent Hassallʼs corpuscles, normal thymopoiesis, myoid cells and 
minimal genomic gains and losses. Lack of AIRE in thymomas very rarely leads 
to the typical manifestations caused by AIRE mutations in APECED, except for 
highly prevalent anti-IFNα and rare anti-Th17 cytokine autoantibodies [92]. 
AIRE deficiency in thymomas might help to create a dangerous environment, 
where thymocytes are activated against autoantigens, which are aberranty 
expressed by neoplastic epithelial cells in most thymomas [89]. 
 
2.2.6. Aireʼs molecular mechanisms 
Several observations conclude that AIRE functions as a transcriptional 
regulator, but the precise molecular mechanisms are poorly understood. AIRE 
protein functional domains and its subcellular localization to nuclear bodies 
reveal its possible role in regulating transcription. So far, all Aire domains have 
reported to participate in transcriptional activation. The transcriptional acti-
vation region has been placed to both PHD fingers [61, 64], CARD and SAND 
domains [57, 62, 93] since mutations in these domains decrease the transacti-
vation capacity of AIRE. 
Initially, it was hypothesized that AIRE might act as a direct transcriptional 
regulator by binding to DNA. A study by Halonen et al. showed that SAND 
domain of AIRE contains NKAR motif and predicted it to be important for DNA-
binding [62]. AIRE has been found to bind to two consensus sequences: (i) a 
tandem repeat of the ATTGGTTAA (G-box) sequence and (ii) a sequence similar 
to the TATA box- TTATTA (T-box) [94], whereas AIRE PHD domains can bind 
to the ATTGGTTAA sequence motif and SAND domain recognizes TTATTA 
motif, respectively [95]. AIRE binding to these motifs was proposed to regulate 
thymic expression of different genes such as cytokines, transcription factors and 
posttranslational modifiers [96]. However, the results by Koh et al. demonstrated 
Aireʼs affinity for nonspecific DNA sequences [97]. Taking into account the large 
number and chromosomal clustering of AIRE regulated TSAs [98, 99], AIRE 
seems to have a more general function rather than being a direct transcriptional 
regulator. Indeed this notion was confirmed when Aire was introduced into 
diverse cell types and very limited transcripts overlapped. This shows that the 
cellular environment dictates which genes are AIRE regulated [100]. 
Several interacting partners for AIRE have been identified in the context of 
transcriptional activation. First the common transcriptional coactivator CREB-
binding protein (CBP) was shown to interact with AIRE through the CH1 and 
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CH3 conserved domains [64]. AIRE and CPB preferentially colocalize to 
nuclear bodies (NB) in cells that lack or have low levels of PML protein [93]. 
CBP and AIRE cooperation might be important for mTEC differentiation be-
cause signalling through RANK (induces AIRE- cells differentiation into AIRE+ 
cells) translocates CBP from the cytoplasm to the nucleus and co-accumulation 
of CBP and AIRE in nuclear dots [57]. 
Following nuclear matrix-associated proteins have been described as 
partners of AIRE: protein inhibitor of activated STAT (PIAS1) [101] and the 
DNA-dependent protein kinase (DNA-PK) [102]. PIAS1 and DNA-PK proteins 
have shown to bind to nuclear-matrix-associated DNA sequences [101, 103]. 
The expression of AIRE enhances the formation of PIAS1 NBs. AIRE and 
PIAS1 NBs are localized adjacent to each other. The concurrent expression of 
PIAS1 and AIRE activates the human insulin promoter and SP-RING (RING 
finger-like domain) is obligatory to conduct this activation. Possibly AIRE and 
PIAS1 associate with a common nuclear complex through other components of 
the nuclear matrix to regulate AIRE target genes [101]. Another AIRE inter-
acting partner DNA-PK, a Ser/Thr kinase, is formed by two Ku regulatory 
subunits, Ku70 and Ku80, and a large catalytic subunit DNA-PKc in the 
presence of DNA [102]. DNA-PK recognises and repairs DNA-double stranded 
breaks (DSB) and phosporylates several proteins involved in regulation of cell 
cycle and transcription [104]. Additionally it was shown that PIAS1 is able to 
promote the reparation of DSBs [105]. DNA-PK phophorylates AIRE protein 
and mutations in AIRE protein phoshorylation sites decrease the capacity of 
AIRE to activate transcription from reporter promoters [102].  
AIRE has been reported to associate with a number of multi-protein comple-
xes involved in transcriptional elongation and the conversion of unspliced pre-
mRNAs to mature mRNAs. AIRE recruits positive transcription elongation 
factor b (P-TEFb) to promoters of target genes with poised RNA polymerase II 
(RNAPII) to enable efficient elongation of primary transcripts [106]. pTEF-b 
consists of the CycT1 and cyclin-dependent kinase 9 (Cdk9) [107]. Active p-
TEFb heterodimer of CycT1 and Cdk9 interacts with AIRE, and CycT1 
partially colocalizes with AIRE in the same nuclear dots [106]. Mammalian 
gene transcription is initiated by the binding of RNA polymerase II to gene 
promoters for correct formation of transcription pre-initiation complex. Parti-
cular complex initiates transcription but does not elongate unless P-TEFb forms 
a complex with RNApolII [108]. Genome-wide studies have established that 
majority of genes have engaged RNApolII at their promoters regardless of their 
activity. Poised RNApolII is mediated by the action of negative elongation 
factors and recruitment of p-TEFb stimulates the transition of RNApolII from 
pausing to productive elongation [107]. 
In a study, Abramson et al. identified AIRE interacting proteins by co-
immunoprecipitation followed by mass spectrometry. The identified wide set of 
Aire associated proteins fall into four major functional classes: 1) nuclear 
transport (e.g., XPO1, NUP93, KPNB1), which are likely to mediate the 
shuttling of Aire into or out of the nucleus; 2) chromatin binding and structure 
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(e.g., histones, the cohesin complex), which could affect the structure or spatial 
organization of chromatin in response to Aire and serve as an access point for 
Aire binding; 3) transcription (DNA-PK, PARP1, TOP2a, FACT and 
RNApolII), which possibly modify the nucleosome environment in response to 
elongating RNApolII; 4) pre-mRNA processing (including several splicing 
factors and RNA helicases). In series of experiments the authors demonstrated 
that AIRE promotes TOP2a-initiated DSBs, which would recruit and activate 
multiple members such as DNA-PK, Ku80, PARP1, and H2AX, as well as 
several other Aire-associated molecules, including SMC1, TRIM28, MSH2/6 
and RUVBL2. TOP2a-initiated DSBs ease superhelical tensions generated by 
advancing RNApolII during transcriptional elongation, which helps it to pro-
ceed more smoothly through the unwinding helix and providing local relaxation 
of the chromatin structure resulting in more efficient mRNA synthesis. Addi-
tionally, Aire enhances processing of pre-mRNAs to mature mRNA [109]. 
AIRE cooperates with p63 in HLA class II expression of mTECs, which is 
linking AIRE and its ability to control the representation of wide set of genes 
from peripheral tissues and organs in the thymus. AIRE and p63 interact 
through the association of a SAND domain of AIRE and transactivation (TA) 
domain of p63. A naturally occurring mutation in SAND domain of AIRE 
abolishes the binding of AIRE to p63 [110]. The expression of HLA class II is 
controlled by a class II master regulator (CIITA) [111]. It was shown that AIRE 
and p63 complex has regulatory role in CIITA expression in mTECs [110]. 
Recently, a new Aire interacting protein called the death-domain-associated 
(DAXX) protein, which exerts strong repressive role on AIRE transcriptional 
activity, was discovered [112]. DAXX is ubiquitously expressed throughout the 
body with particular high expression in the thymus and testes. In the nucleus 
DAXX is found to associate with PML NBs and together with PML the protein 
influences apoptosis and transcription, whereas in cytoplasma interacts with 
various proteins involved in cell death regulation [113]. DAXX is known to 
associate directly and repress several transcription factors, e.g. ETS1 [114], 
NFkB [115], p53 and its family members p63 and p73 [116]. DAXX has been 
found to take part of a large multiprotein complex that includes core histones 
(H2A, H2B, H3 and H4) and histone deacetylase II (HDAC II) and DAXX-
mediated transcriptional repression is due to interaction with HDAC [117]. 
AIRE and DAXX colocalize in the nucleus, and DAXX represses the 
transcriptional activation property of AIRE to induce the expression of the 
insulin promoter. AIRE is able to interact with HDAC1 and HDAC2 and 
thereby it is suggested that histone deacetylation by HDACs is involved in 
DAXX-mediated repression of AIRE transcriptional activity [112]. 
AIRE has been reported to act as a histone code reader sensing epigenetic 
chromatin modifications. Two studies demonstrated that AIRE binds directly to 
unmethylated histone H3 lysine 4 (H3K4) by PHD1 domain and binding is 
necessary for the up-regulation of genes encoding TSAs [97, 118]. Next, AIRE 
was shown preferentially activate tissue-specific genes that are characterized by 
low levels of initial expression and lack active chromatin marks, such as histone 
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H3 trimethylation (H3K4me3) and acetylation (AcH3) on their promoters. 
During activation by AIRE, the target genes acquire histone H3 modifications 
associated with transcription and RNApolII, and H3K4me3 levels are increased 
on AIRE promoter during mTEC differentiation [119]. Transcriptional regu-
lation by AIRE through its interactions with histone H3 is confined to the first 
N-terminal residues in H3 tail [120]. Overexpression of Aire and the H3K4-
specific demethylase yielded unexpected results, showing that Aireʼs transcrip-
tional footprint remained largly unchanged, with only a partial derepression of a 
subset of genes already accessed by Aire. These results argue that Aireʼs PHD1 
and H3K4 interaction is not sufficient for Aire to productively target a given 
gene [121]. It would be important to biochemically confirm upstream and 
downstream interacting proteins which cooperate with AIRE to have more 
profound understanding of Aire targeting and function in context of expression 
of TSAs and mediating central tolerance. 
 
2.3. Epigenetic modifications  
in regulation of gene expression 
Epigenetics has emerged to explain how cells with a limited number of genes can 
differentiate into different cell types and how phenotype is passed to daughter cells. 
Epigenetics is defined as the study of stable and heritable changes in gene 
expression that do not involve alterations in DNA sequence. Epigenetic processes 
control gene expression patterns during cell cyle, differentiation and development in 
response to environmental and biological modifications [122]. Epigenetic state 
changes with age and maybe be critical determinant of cellular senscence and 
organism aging [123]. Epigenetic mechanisms have many layers of complexity, 
including chromatin remodelling and RNA transcripts and their encoded proteins. 
Epigenetic modifications fall into two main categories such as DNA methylation 
and posttranslational modification of histones. 
2.3.1. Chromatin 
Chromatin is the combination of genomic DNA and histone proteins, in which 
DNA is packed approximately 10 000-fold. The basic repeat unit for chromatin 
is the nucleosome that is typically composed of an octamer of the four core 
histones H2A, H2B, H3 and H4 and 146 bp of DNA wrapped twice around the 
histones. The protein octamer is divided into four dimers defined by H2A-H2B 
and H3-H4 histone pairs [124]. Noncondensed nucleosomes are connected by 
small segments of linker DNA forming "beads on a string“ structure, which is 
stabilized by the histone H1. Histone H1 seals two rounds of DNA on the 
surface of the nucleosome core and repeating nucleosomal units are folded into 
higher-order chromatin fibers [125]. Each core histone is composed of a 
structured domain and an unstructured amino-terminal tail of 25–40 residues 
that surrounds the nucleosomes. Histone tails provide sites for different post-
translational modifications (PTMs) such as methylation, acetylation and 
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phosphorylation, which are all involved in gene-specific regulation [126]. 
Nucleosomes are organized, mobilized and remodeled by regulatory proteins, 
chromatin remodelling factors and histone modifying enzymes, which 
determine the accessibility of DNA to other regulatory factors (Figure 4). 
Chromatin remodelling complexes (remodellers) are specialized multi-
protein machines that enable access to the nucleosomal DNA by altering the 
structure, composition and positioning of nucleosomes and influence the regu-
lation of gene expression. The remodellers use the energy of ATP hydrolysis for 
breaking histone-DNA contacts, making DNA more accessible for various 
regulatory proteins. There are currently four different families of chromatin 
remodellers: SWI/SNF (switching defective/sucrose nonfermenting), ISWI 
(imitation switch), CHD (chromodomain, helicase, DNA binding), and INO80 
(inositol requiring 80), which have different compositions and execute different 
tasks. In addition, remodellers are also utilized for many steps of DNA repair 
and DNA replication [127]. 
 
 
 
Figure 4. Chromatin structure and gene regulation. X is a transcriptionally active gene 
with an open chromatin structure and sparse DNA methylation (brown circles), Y is a 
transcriptionally silent gene with a closed chromatin structure and dense DNA 
methylation (brown circles). Histone tails provide sites for different posttranslational 
modifications (green and pink circles). Nucleosomes are organized, mobilized and 
remodeled by regulatory proteins, chromatin remodelling factors and histone modifying 
enzymes (green and red protein complex). Modified from [128]. 
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2.3.2. Histone modifications 
The surface of nucleosomes is covered with multiplicity of histone modifications. 
So far 8 different classes of modifications have been described such as acetylation, 
methylation (lysines and arginines), phosphorylation, ubiquitylation, SUMOylation, 
ADP ribosylation, deimination and proline isomerization. Different combinations of 
modifications gives wide variety of functional responses, which in turn depend on 
the signalling conditions within the cell. After stimulus, transcription factors are 
engaged to the promoter of specific genes and result in modification events. 
Modification events can be divided into those that correlate with activation such as 
acetylation, methylation phoshorylation and ubiquitination; and those that correlate 
with repression, for example, methylation, ubiquitination, SUMOylation, 
deimination and proline isomerization. Acetylation, methylation and phospho-
rylation are the best studied modifications [129]. 
The regulation of gene expression within euchromatin involves the delivery 
of chromatin-modifying enzymes by DNA-bound transcription factors. Chro-
matin modifying complexes are responsible for adding or removing covalent 
modifications on histone proteins. Most studied chromatin modifying comple-
xes are histone acetyltransferases (HAT) and histone deacetylases (HDAC). 
 
2.3.2.1. Histone acetylation and deacetylation 
One of the features of actively transcribed genes is the acetylation of the amino-
terminal tails of histones, which is found mostly at promoters and the 5ʼregions 
of genes, with the level of acetylation correlating with the rate of transcription. 
Different acetylations may target different regions of genes. For instance, 
H3K9ac is located in the region surrounding the transcription start site, whereas 
H3K4ac is elevated in the promoter and transcribed regions of active genes 
[130]. Acetylation of lysine residues results in neutralization of charge of 
histone tails and leads to loose contact between histone and DNA that makes 
DNA more accessible for transcription factors. Histone acetylation is catalyzed 
by class of enzymes known as HATs, which use acetyl-CoA as a substrate to 
acetylate lysine residues in histones. Several HAT families are indentified, 
including GNAT (Gcn5 N-acetyltransferases), p300/CBP and MYST [131]. All 
known HATs contain bromodomain, which functions as acetyl-lysine binding 
domain [132]. Histone acetylation performs a crucial role in DNA replication, 
recombination and repair. Various signalling events may change the association 
partners from HATs to HDACs [133]. 
Histone deacetylation has an opposite effect to acetylation and is generally 
associated with the transcriptional respression by the removal of acetyl groups 
from histone tails. HDACs are recruited to promoters via interaction with 
specific DNA-binding transcription factors. There are four families of HDACs 
(classes I to IV) [134]. Previously HDACs have been associated with inactive 
genes, but genome-wide mapping of HATs and HDACs revealed that both 
HATs and HDACs were found at active genes with acetylated histones, and 
targeted to transcribed regions by phosphorylated RNApolII. Inactive but so 
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called poised genes acquired H3K4 methylation before dynamic cycling of 
acetylation and deacetylation by transient HAT/HDAC binding, preventing 
RNApolII binding but poising for future activation [135]. 
 
2.3.2.2. Histone phosphorylation 
Core histone phosphorylation has been described to have a role in transcription, 
mitosis, DNA repair and apoptosis. The most characterized phosphorylation 
events are phosphorylation of serine 10 and serine 28 in histone H3 and 
phosphorylation of the H2A.X, whereas several tyrosine phosphorylations 
within the H3 protein have been recently described. Each phospho-H3 modi-
fication has a specific kinase that mediates phosphorylation of a particular 
residue in H3. In mammalian cells, the phosphorylation is believed to have two 
opposite roles: one in the initiation of mitotic chromosome condensation and the 
other in localized chromatin decondensation leading to gene activation [136]. 
The contribution of phosphorylation to transcriptional activation is not well 
understood. It is thought that the addition of negatively charged phosphate 
groups to histone tails neutralizes the basic charge of histone tails and reduces 
their affinity towards DNA. 
 
2.3.2.3. Histone methylation 
There are two types of histone methylation, targeting either lysine or arginine 
residues. Modifications by lysine methyltransferases (MLL, SUV39, SET, etc) 
either activate or repress of transcription [137]. Lysine methylation can have 
different effects depending on which residue is modified. Three methylation 
sites on histones are associated with transcription activation such as H3K4, 
H3K36 and H3K79. The last two modifications are marks of transcriptional 
elongation. Histone modifications H3K9, H3K27 and H4K20 are connected to 
transcriptional repression by recruiting methylating enzymes to repressed genes 
[129]. Methylation is antagonized by histone demethylases (LSD, JHDM, 
JMJD, etc) selective for mono-, di-, or trimethylated lysines, which allows 
larger functional control of lysine methylation [138]. 
Histone arginine methylation is also involved in activation or repression of 
transcription and catalyzed by protein arginine methyltransferases (PRMTs). In 
mammals, PRMT1- and CARM1-catalyzed histone arginine dimethylation is 
involved in gene activation, while PRMT5-catalyzed histone arginine di-
methylation is associated with gene repression. Arginine methylation is required 
for development, cellular proliferation and differentiation [139]. 
 
2.3.3. DNA methylation 
Mammalian genome globally has less CpG dinucleotides than expected, except 
at short DNA stretches called CpG islands (CGI), which are associated with 
gene promoters. Originally CpG islands were defined as regions of at least 200 
bp with a (GC)-content of at least 50% and a ratio of observed CpG frequency 
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to expected frequency of at least 0.6 [140]. In recent years a large class of CpG 
islands (orphan CGIs) were discovered that are remote from annotated 
transcription start sites, but show evidence for promoter function [141, 142]. 
These novel findings, the colocalisation of a CGI with bound RNA polymerase 
II, highlight the strong connection between CGIs and transcription initiation. 
The accurate performance of gene expression during differentiation and 
development requires three types of regulatory DNA elements: core promoters, 
upstream promoter elements and enhancers [143]. Core promoters  support the 
formation of relatively large multiprotein complexes that direct the RNA 
polymerase II to start transcription at accurate site [144]. Upstream promoter 
elements are situated within the first 100–200 nucleotides upstream of the core 
promoter and contain transcription factor binding sites to increase the rate of 
transcription by promoting assembly of pre-initiation complexes [145]. En-
hancers locate either downstream or upstream of the promoter, on the same or 
different chromosomes, and promote the rate of transcription from promoter and 
define the expression pattern of the genes [146]. Mammalian transcription 
factor-binding sites are more CG-rich than the bulk genome and many contain 
CpG in their recognition site. The studies imply that the CpG-containing 
transcription factor-binding sites regulate the expression of genes with im-
portant roles in pathways leading to cell-type-specific gene expression and in 
pathways controlled by the complex networks of signalling systems [147]. 
Furthermore, it has become clear that chromatin is a dynamic and active 
participant in transcriptional regulation and its structure determines the 
accessibility of a gene`s promoter and depends on DNA methylation and histone 
modifications. During the development, DNA methylation and specific histone 
modifications influence each other: histone methylation may direct DNA 
methylation patterns, and DNA methylation directs the establishment of certain 
histone modifications. Early studies have demonstrated that isolated CGI 
chromatin showed high levels of histone H3 and H4 acetylation, which represents 
transcriptionally active chromatin. The genome-wide studies have revealed that 
trimethylation of H3K4 is a signature histone mark of CGI promoters even in the 
state of inactivity [148]. In mammals, four DNA methyltransferases (DNMTs) 
have been identified: DNMT1, DNMT3A, DNMT3B, and DNMT3L. DNMT1 
acts mainly as a "maintenance“ methyltransferase during the DNA synthesis, and 
DNMT3A and DNMT3B have preference for unmethylated CpG dinucleotides 
and perform de novo methylation during the development. DNMT3L increases 
the ability of de novo methyltransferases to bind to the methyl-group donor and 
stimulate their activity, whereas DNMT3L has no catalytic activity itself [149]. 
Trimethylation of H3K9, H3K27, and H4K20 has been suggested to be needed as 
a prior condition for subsequent DNA methylation. In the context of H3K9 and 
H3K27, the relevant histone lysine methyltransferases, SUV39H1/2 and EZH2, 
interact directly with DNMT1, DNMT3A and DNMT3B. The additional link 
between DNA methylation and the histone code is methyl-CpG-binding proteins 
(MBDs), which interact specifically with methylated DNA and mediate 
transcriptional repression [149]. 
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3. AIMS OF THE STUDY 
 
The aims of the present study were: 
1.  To examine whether modulation of Aire regulates the expression of tissue 
specific antigens. 
2.  To study if Aire infuences the expression of ligands of chemokine receptor 
CCR4 and CCR7. 
3.  To determine DNA methylation signatures of the AIRE promoter in thymic 
epithelial cells, thymomas and normal tissues. 
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4. MATERIALS AND METHODS 
4.1. Mice and cell culture 
Aire deficient mice (C57BL/6J and Balb/c background) were generated at The 
Walter and Eliza Hall Institute (Melbourne, Australia) via homologous 
recombination of targeting vectors in mouse embryonic stem cells [150]. Thy-
muses and/or inguinal lymph nodes from 4- to 6-week old WT, Aire hetero-
zygote (HET) and Aire-deficient (KO) mice were used. Embryonic (E13.5, 
E15.5 and E17.5), newborn, neonatal D11 and adult (6 weeks, 6 months and 12 
months) mouse tissues were used in developmental dynamics analysis in study 
1. In development analysis in study 2, the ages of mice were the same with 
exception of neonatal D10. The CCR7-deficient C57BL/6 mice were obtained 
from The Jackson Laboratory. All mice used in the studies 1 and 2 were bred 
and maintained at the mouse facility of the Institute of Molecular and Cell 
Biology, University of Tartu. 
Mouse thymic epithelial cells TEC 1C6 (kindly provided by G. Holländer, 
University of Basel, Switzerland), human embryonic kidney HEK293 (obtained 
from ATCC) and thymic primary culture (made in-house as in 4.3. Mouse 
thymic stromal cell isolation and cell sorting) cells were cultured in Dulbeccoʼs 
modified Eagleʼs medium (DMEM) supplemented with 10% fetal calf serum 
(FCS), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphote-
ricin B (Gibco BRL). 
 
 
4.2. EGFP and Aire adenovirus construction  
and infection 
The pAdTrack-CMV (Stratagene, La Jolla, CA, USA) vector expressing en-
hanced green fluorescence protein (EGFP) gene was used as pAd-GFP plasmid. 
The mouse Aire gene was amplified from pCAIRE vector [72] using the primers: 
mAire-5-SalI and mAire-3-NotI stop (Table 2) and cloned into SalI and NotI sites 
of pAdTrack-CMV resulting in AdAire-GFP. HEK293 cells (Invitrogen, 
Carlsbad, CA, USA), which constitutively express AdEasy deleted E1 genes in-
trans, were used for expression analysis of adenoviral vectors and for virus 
growth. To make recombinant adenoviruses, pAd-GFP and pAdAire-GFP 
plasmids were recombined with pAdEasy-1. The amplification and harvest 
process was repeated to generate higher titer viral stocks. Subsequently, the 
lysates from several amplification steps were purified by CsCl gradient 
centrifugation [151]. Virus bands was collected and mixed with 2× preservation 
buffer (10mM Tris pH 8.0, 100mM NaCl, 0.1% BSA, 50% glycerol). We quan-
tified the Ad-GFP and AdAire-GFP virus particles by absorbance measurement at 
260 nm to be equivalent to 1012 particles with virus titers >2×108 pfu/ml. The 
adenoviruses were next verified for their expression by infection of HEK293 cells 
for 48 h and analyzed by immunoblotting with rabbit polyclonal anti-mouseAire 
and mouse monoclonal anti-G3PDH (Ambion, Austin, Texas, USA). The signal 
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was detected by Supersignal® West Pico Chemoluminescent Substrate (Pierce 
Biotechnology, Rockford, IL, USA) according to the manufacturerʼs instructions. 
For adenoviral infection of thymic primary culture and TEC 1C6, the cells 
were infected with Ad-GFP and AdAire-GFP at approximately 70% confluence. 
Cells were incubated in 500 µl serum-free OptiMEM (100 U/ml penicillin,  
100 µg/ml streptomycin and 0.25 µg/ml amphotericin B) and infected with 
equal amounts of virus for 1 h. The infection rate was further assessed by 
quantitative real-time PCR analyzing intake of viral genomic DNA. 
The cells were then collected after 48h using trypsin-EDTA and assessed for 
infection rate by quantifying the percentage of GFP-positive cells in Ad-Aire-
GFP- or Ad-GFP infected TECs by a FACSCalibur (BD Biosciences, San Jose, 
CA, USA). RNA was isolated from the cells using TRIzol followed by reverse 
transcription and qPCR as described above [152]. 
 
 
4.3. Mouse thymic stromal cell isolation 
Small cuts were made into the capsules of thymi dissected from eight to twelve 4-
week-old mice and thymocytes were released by repetitive pipeting. The 
remaining thymic fragments were incubated in 0.5 mg/ml dispase/collagenase 
(Roche, Basel, Switzerland) and 1.5µg/ml DNase I (AppliChem, Darmstadt, 
Germany) in PBS at 37 °C for 20 min, with gentle agitation using a Pasteur 
pipette every 5 min. Released cells were collected to separate fractions and fresh 
enzyme solution was added four times. The cells were resuspended in 5mM 
EDTA in 10ml of RPMI-1460. Isolated cells were used either for stromal cell 
isolation or for growing thymic primary culture. For thymic primary culture, the 
isolated cells were cultured for 4 days in DMEM supplemented with 10% FCS 
and incubated 37°C, 5% CO2. For stromal cell isolation cells were counted in 
each fraction. To obtain 2×108 cells required for isolation, the final fraction was 
used first and then collected backwards through the collected fractions. The 
fractions were pooled and passed through a 100 µm mesh to remove clumps. 
 
 
4.4. Human tissue samples and isolation  
of thymic cell populations 
Normal peripheral tissue samples (cerebellum, uterus, lung, kidney, myocardium, 
gray matter, spleen and liver from 4 donors (marked as D1-D4) over 50 years of 
age) were obtained from the Tartu University Tissue Bank, Estonia. Thymomas 
(six WHO type A thymomas, five type AB thymomas and five type B3 
thymomas, age unknown) were supplied by the cryo-archives of the Institute of 
Pathology, University of Würzburg, Germany. In addition to tumor tissue, 
residual normal non-neoplastic thymus tissue of adult (32–67 years old) thymoma 
patients was analyzed, supplied by the University of Heidelberg. TECs were 
purified from thymus samples of children undergoing corrective heart surgery (6 
weeks to 5 years old) at the Department of Heart Surgery, Medical School 
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Heidelberg and Tartu University Clinic (Table 1). The study was approved by the 
local ethical committees of the Universities of Heidelberg, Würzburg and Tartu. 
Human medullary thymic epithelial cells (mTECs) and cortical thymic epithelial 
cells (cTECs) were purified as described previously [98]. 
For AIRE promoter methylation studies we purified epithelial cell subsets 
from human thymus tissue. We used the CD45 marker to deplete human thymic 
samples from all cells of hematopoietic origin. Subsequent cell sorting with 
EpCAM and CDR2 markers was used to divide thymic epithelial cell popu-
lations corresponding to immature MHC class IIlo mTEC (EpCAMhi, CDR2lo, 
MHC class IIlo),  mature MHC class IIhi mTEC (EpCAMhi, CDR2lo, MHC class 
IIhi) and cTEC (EpCAMlo, CDR2hi). 
For Q2chip experiment thymic pieces from 2-wk to 6-month old patients were 
dissected and collected into RPMI 1640. Connective tissue was removed and small 
cuts were made into the capsule of thymic piece and the thymocytes were released 
by repetitive pipetting. The remaining thymic fragments were incubated in 0.5 
mg/ml dispase/collagenase (Roche, Basel, Switzerland) and 5 µg/ml DNase I 
(AppliChem, Darmstadt, Germany) in PBS at 37°C for 20 min with gentle 
agitation. The released cells were collected as separate fractions and fresh enzyme 
solution was added, this cycle was repeated four times. All cell fractions were 
pooled and subsequently enriched for CD45- cells by a depletion step using CD45 
microbeads (Miltenyi Biotec, Hilden, Germany) and the AutoMACS system 
(Miltenyi Biotec, Hilden, Germany) according to the manufacturerʼs instructions. 
The positive fraction was collected and served as a thymocyte-enriched fraction for 
the Q2chip experiments. The CD45-negative fraction was subsequently stained 
with anti-EpCAM microbeads (Miltenyi Biotec, Hilden, Germany) and positively 
MACS-sorted. This fraction was highly enriched in mTECs. 
 
 
Table 1. Human tissue samples and thymic cell populations by age and source.  
 
Material Age Number  of patients Source 
cerebellum >50 years 2 Tartu University Tissue Bank 
uterus >50 years 2 Tartu University Tissue Bank 
lung >50 years 2 Tartu University Tissue Bank 
kidney >50 years 2 Tartu University Tissue Bank 
myocardium >50 years 3 Tartu University Tissue Bank 
gray matter >50 years 2 Tartu University Tissue Bank 
spleen >50 years 1 Tartu University Tissue Bank 
liver >50 years 1 Tartu University Tissue Bank 
thymoma unknown 
6 A type, 5 
AB type, 5 B3 
type 
University of Würzburg 
normal (non-
neoplastic) thymus 32–67 years 5 University of Heidelberg 
TEC 6 weeks to 5 years >10* 
Medical School Heidelberg Tartu 
University Clinic 
* means TECs used in different experiments such as cell sorting and Q2ChIP. 
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4.5. Immunofluorescence and microscopy 
Cryostat sections (5 μm) of fresh-frozen 10-day-old mouse thymus were thaw-
mounted onto SuperFrost Plus microscopeslides (Menzel–Gläzer) and fixed in 
cold acetone (−20 ◦C) for 5 min. Sections were permeabilized in PBS/0.5% 
Triton X- 100/1% normal goat serum (DAKO) for 15 min. Slides were blocked 
with 1% normal goat sera for 20 min at room temperature and incubated with 
rat monoclonal G8.8 (1:100) (provided by Andy Farr, University of Washing-
ton, USA) or rabbit polyclonal anti-mAIRE (1:2000) [72] and then incubated 
with Alexa Fluor 594-conjugated goat anti-rat IgG (H + L) or Alexa Fluor 488-
conjugated goat anti-rabbit (Fab)2 (both from Invitrogen- Molecular Probes Inc, 
Eugene, OR, USA), followed by washing six times in PBS. The slides were 
incubated with 15 μg/ml DAPI (Roche, Basel, Switzerland) and mounted with 
fluorescent mounting medium (DAKO). The images were acquired by fluore-
scence microscopy (Eclipse TE2000–4; Nikon, Melville, NY, USA). 
 
 
4.6. Thymic reaggregate organ culture 
Reaggregated thymic organ-cultures were done as described previously [153]. 
Briefly, thymic stromal cells from E17.5 C57BL/6 mice were prepared by 
disaggregating fetal thymic lobes, which had been previously cultured for 7 
days in 1.45mM deoxyguanosine (Sigma, St. Louis, MO, USA) and dissagre-
gation was done by using 1× trypsin 30 min (Life Technologies, Grand Island, 
NY, USA). Reaggregates were formed by mixing together stromal cells and 
thymocytes at a 3:1 cell ratio and cultured for 3 days at 37 °C. 
 
 
4.7. Quantitative real time PCR 
RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA, Life Techno-
logies) and reverse-transcribed to cDNA using the SuperScriptTM III Reverse 
Transcriptase (Invitrogen, Carlsbad, CA, USA, Life Technologies). Real-time 
PCR was performed with the ABI Prism 7900HT Fast Real-Time PCR System 
instrument (Applied Biosystems, Foster City, CA, USA) using qPCR SYBR 
Green Core Kit (Eurogentec, Liege, Belgium) according to the manufacturerʼs 
instructions except that 2mM MgCl2 concentration was used. The amplification 
program included an initial denaturation step at 95 °C for 10 min, followed by 
denaturation at 95 °C for 15 s, and annealing and extension at 60 ◦C for 1 min, 
for 45 cycles. SYBR Green fluorescence was measured after each extension 
step, and the specificity of amplification was evaluated by melting curve 
analysis. The relative gene expression levels were calculated using the compa-
rative Ct (ΔCt) method (according to Applied Biosystems, Foster City, CA, 
USA), where the relative expression is calculated as 2−ΔΔCt , and where Ct repre-
sents the threshold cycle. Every sample was run in three parallel reactions. 
Quantitative qRT-PCR primer sequences used in the study are listed in Table 2. 
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In chemokine expression assessment in whole thymi and lymph nodes, and 
over-expression of Aire induces chemokine expression the Student t-test, 
p<0.05, was used (GraphPad Prism 5 version). 
 
 
4.8. DNA isolation and bisulfite genomic  
DNA sequencing 
Genomic DNA was extracted from peripheral tissues, sorted thymic cell popu-
lations using JETQUICK Tissue DNA Purification Kit (Genomed, Löhne, Ger-
many) or by phenol/chloroform extraction (briefly, add equal volume on 
phenol/chloroform to DNA solution, mix the top layer with equal volume of 
chloroform and precipitate DNA with 96% ethanol, wash with 70% ethanol and 
dissolve the material in destilled water). The DNA was bisulfite treated using 
EpiTect Bisulfite kit (Qiagen, Hilden, Germany) according to the manufactu-
rerʼs instruction. This reaction converts all non-methylated cytosine bases into 
uracil. Traditional sodium bisulfite treatment was performed on neoplastic 
thymus samples and normal thymuses from cardiac surgery patients. The 
conversion efficiency of EpiTect Bisulfite kit was compared with traditional 
conversion method using HeLa cell-line and the kit was used to treat sorted 
thymic cell population. Briefly, 2 µg of genomic DNA was denaturated with  
2 M NaOH for 10 min, followed by incubation with 3 M sodium bisulfite and 
10 mM hydroquinone for 16h at 50°C. After treatment, DNA was purified using 
a NucleoSpin Extract II kit (Macherey-Nagel, Düren, Germany), precipitated 
with ethanol, and resuspended in 30 µl of distilled water. Two µl of the aliquot 
were used as a template for PCR. AIRE promoter region was amplified using 
BITSA primers as listed in [68]. Amplified DNA fragments were purified with 
NucleoSpin Extract II kit, cloned into pGEM-T (Promega, WI, USA) or TOPO 
TA (Invitrogen, Carlsbad, CA, USA, Life Technologies) vector and individual 
clones were sequenced in University of Melbourne and University of Tartu. Se-
quence alignment was performed using ClustalW (http://www.ebi.ac.uk/clustalw/). 
 
 
4.9. Q2ChIP 
Quick and quantitative ChIP (Q2ChIP) was carried out as described earlier 
[154] using protein G-sepharose beads (GE Healthcare, Munich, Germany) pre-
blocked with 100 μg/ml BSA and 500 μg/ml salmon sperm DNA. Cells were 
fixed with formaldehyde and sonicated as in [119]. Sonicated supernatant 
containing chromatin of 17,6–22,4 x 103 cells, depending on the size of donated 
thymus and sorting efficiency, was immunoprecipitated using antibodies to H3 
(ab1791), H3K4me3 (ab8580) (Abcam, MA, USA); H3K27me3 (Millipore, 
Billerica, MA, USA); purified rabbit IgG (PP64) (Millipore). Material from 
18 000–20 000 cells was used for one immunoprecipitation. Precipitated DNA 
was extracted with the mix of phenol-chloroform isoamylalcohol (25:24:1). 
ChIP samples were analyzed in triplicates by quantitative PCR using Maxima 
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SYBR Green/ROX qPCR Master Mix (Fermentas, Vilnius, Lithuania) on ABI 
Prism 7900HT (as in 4.7. Quantitative real time PCR) . The results were 
analyzed using comparative Ct method (Applied Biosystems, Foster City, CA, 
USA). Datasets of each primer pairs were normalized to ChIP input values and 
thereafter the histone modification results were normalized to H3. Sequences of 
the qRT-PCR primers used in this study are listed in Table 2. 
 
 
4.10. Primer sequences 
The sequences of all primers (TAG Copenhagen, Copenhagen, Denmark) used 
in the study are listed in Table 2. 
 
 
Table 2. Primers used in the study together with corresponding sequence, species, gene 
and application of use. 
 
Oligo name Sequence Species Gene Application 
mAire-5-SalI tttgtcgac agatggcaggtggggatggaatg mouse Aire PCR 
mAire-3-NotI stop tttgcggccgctcaggaagagaagggtggtgtc mouse Aire PCR 
K2–8 sense aggagctcattccgtagctg mouse K2–8 qPCR 
K2–8 antisense tctgggatgcagaacatgag mouse K2–8 qPCR 
Aire 11/12 ccccgccggggaccaatctc mouse Aire qPCR 
Aire 12/13 ccccgccggggaccaatctc mouse Aire qPCR 
Tff3 sense tacgttggcctgtctccaag mouse Tff3 qPCR 
Tff3 antisense cagggcacatttgggatact mouse Tff3 qPCR 
Ins2 sense gacccacaagtggcacaac mouse Ins2 qPCR 
Ins2 antisense tctacaatgccacgcttctg mouse Ins2 qPCR 
Mup1 sense tctgtgacgtatgatggattcaa mouse Mup1 qPCR 
Mup1 antisense tctggttctcggccatagag mouse Mup1 qPCR 
Spt1 sense aacttctggaactgctgattctg mouse Spt1 qPCR 
Spt1 antisense gaggcctcattagcagtgttg mouse Spt1 qPCR 
CCL-5 sense gtgcccacgtcaaggagtat mouse CCL5 qPCR 
CCL-5 antisense cccacttcttctctgggttg mouse CCL5 qPCR 
CCL-17 sense agtggagtgttccagggatg mouse CCL17 qPCR 
CCL-17 antisense ccaatctgatggccttcttc mouse CCL17 qPCR 
CCL-22 sense ctgatgcaggtccctatggt mouse CCL22 qPCR 
CCL-22 antisense ggagtagcttcttcacccag mouse CCL22 qPCR 
CCL-19 sense ctgcctcagattatctgccat mouse CCL19 qPCR 
CCL-19 antisense cttccgcatcattagcaccc mouse CCL19 qPCR 
CCL-21 sense ccctggacccaaggcagt mouse CCL21 qPCR 
CCL-21 antisense aggcttagagtgcttccggg mouse CCL21 qPCR 
CCL-25 sense gtgctgtgagattctacttcc mouse CCL25 qPCR 
CCL-25 antisense tatggtttgacttcttcctttcag mouse CCL25 qPCR 
β2m sense tgagactgatacatacgcctgca mouse β2m qPCR 
β2m antisense gatgcttgatcacatgtctcgatc mouse β2m qPCR 
AIREprF caagcgaggggctgccagtg  human AIRE Q2ChIP 
AIREprR gcgatctccgtgcggtgcag  human AIRE Q2ChIP 
chAIRE 4int F tccagagaccccctatctcc human AIRE Q2ChIP 
chAIRE 4int R aggaaggcatgaccaatgac  human AIRE Q2ChIP 
chAIRE 4int R ttaagagcatggcgtttggt  human AIRE Q2ChIP 
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Oligo name Sequence Species Gene Application 
chAIRE 8ex F cattcccagtggatccttga human AIRE Q2ChIP 
chAIRE 8ex R caaggtcagtgccgcagggg human AIRE Q2ChIP 
chAIRE 12int F caaggtcagtgccgcagggg  human AIRE Q2ChIP 
chAIRE 12int R gcaagccctcgaagctggca human AIRE Q2ChIP 
chAIRE 14ex F cttgtcagtgctcggctgta human AIRE Q2ChIP 
chAIRE 14ex R agtaggtcaccaggcaagga human AIRE Q2ChIP 
hGAPDH_prom_F tactagcggttttacgggcg  human AIRE Q2ChIP 
hGAPDH_prom_R acaggaggagcagagag cga  human AIRE Q2ChIP 
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5. RESULTS 
5.1. Modulation of Aire regulates the expression  
of tissue-specific antigens (I) 
5.1.1. Tissue-specific antigen expression is dependent  
on the Aire gene copy number 
Intrathymic expression of TSAs has been viewed as the key element in the 
induction of central tolerance and a central role for the Aire has been suggested 
in this process. In 2002, Anderson et al. showed that the Aire gene promotes the 
promiscuous expression of peripheral TSAs. The conducted study demonstrated 
autoimmune manifestations in Aire KO mice that depended on lack of Aire in 
mTECs and specific reduction in mRNA levels of peripheral TSAs in mTECs 
[52]. It was followed by array results that showed decreased TSA mRNA levels 
in Aire KO mouse [83]. Thereof, we selected four genes; trefoil factor 3 (Tff3), 
insulin 2 (Ins2), salivary protein 1 (Spt1) and major urinary protein 1 (Mup1) 
representing TSAs downregulated in Anderson et al. and Derbinski et al. array 
data, to study whether in the level of the thymus the TSA expression is 
dependent on Aire. The qRT-PCR values were normalised to the expression 
level of keratin 8 (K8) mRNA, which in thymus is specifically expressed in 
epithelial cell fraction and according to microarray data is not influenced by 
Aire gene. To exclude possible genetic background effects on TSA expression 
levels, the 4 TSAs were also analyzed in thymi from Balb/c WT, Aire hetero-
zygous (HET) and Aire-deficient (KO) mice (Figure 5).  
 
 
 
Figure 5. Dose-dependent effect of Aire on TSA expression in C57Bl/6 and Balb/c 
mice. The whole thymuses from WT, Aire heterozygous (HET) and Aire-deficient (KO) 
mice were analyzed for TSA gene expression by qRT-PCR. 
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The qRT-PCR analysis showed almost complete absence of TSA mRNA signal in 
C57BL/6 and Balb/c Aire-deficient  thymus samples for all 4 TSAs studied (Figure 
4). Moreover, Aire allele dose-dependency was observed, as heterozygous mouse 
thymus consistently had lower expression levels compared to the WT thymus 
levels. The expression level of all four TSAs in heterozygous mice thymus was 
around 10–20% of the expression level in WT mice in both strains, which does not 
correlate with Aire gene copy number for unknown reason. The results showed a 
clear Aire allele dose-dependency for Tff3, Ins2, Spt1 and Mup1 and confirmed 
that genetic background has no influence on Aire-dependent TSAs. 
Next we quantified the TSA expression in lymph nodes from C57Bl/6 mouse 
to determine if Aire has similar effect on TSA expression (Figure 6) in the 
peripheral immune system. 
 
 
            
 
Figure 6. Expression of Aire and Ins2 in the lymph nodes. Thymuses or inguinal lymph 
nodes were collected from 4 to 6-week-old C57BL/6 mice and analyzed for Aire or Ins2 
expression by qRT-PCR. (A) Aire expression was higher in the lymph nodes compared 
to the whole thymus of WT mice. (B) The expression of Ins2 was unaffected in the Aire 
KO mice compared to the WT mice. Data are mean with S.E.M. of triplicate mea-
surements of one out of two representative experiments. 
 
 
The detected Aire mRNA level in the lymph nodes was even higher than the one 
of the whole thymus (Figure 5A), whereas most of the analyzed TSAs were un-
detectable or close to the detection limit. The increase was in relative Aire mRNA 
level, since the expression of the epithelial cell marker K8 was very low in the 
lymph nodes. However, the mRNA signal for the Ins2 was present in lymph node 
but was unaltered in the Aire KO compared to the WT mice. Thus, Ins2 
expression in lymph nodes did not depend on the presence of Aire (Figure 5B). 
To assess Aire co-localization in the thymus with cell-surface marker 
EpCAM the thymus sections were stained with anti-EpCAM and anti-Aire anti-
bodies, and nuclei were identified with DAPI (Figure 7A). The medullary 
compartment of thymus was distinctly characterized by high EpCAM ex-
pression and Aire-positive cells. Next, thymuses were enzyme digested and 
FACS-sorted to mTEC and cTEC population to analyse the expression level of 
Aire and TSAs by qRT-PCR (Figure 7B). 
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Figure 7. TRA expression in mTEC vs. cTEC populations of WT and Aire KO mice. 
(A) Thymuses stained with anti-EpCAM and anti-Aire antibodies were analyzed by 
immunofluorescent microscopy or (B) enzyme digested and FACS-sorted respectively 
to the EpCAM expression and analyzed for the expression level of TSAs in mTEC and 
cTEC populations of WT and Aire KO mice by qRT-PCR. Data in (B) are mean with 
S.E.M. of triplicate measurements of one out of two representative experiments. 
 
 
The expression of the Tff3, Ins2, Mup1 and Spt1 antigens was limited to the 
mTEC population, i.e. the cell population of Aire expression. The cTEC 
population demonstrated very low expression for all four TRAs studied, both in 
the WT as well as Aire KO mouse. 
Combined, these data show that Aire dose-dependently regulates TSA 
expression in thymus (but not in the lymph nodes), and confirms by qRT-PCR 
the previously published microarray data, suggesting that both Aire and TSAs 
are predominantly expressed by mTECs in thymus. 
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5.1.2. TSAs follow the expression of Aire during thymus 
development and involution 
Hypothesizing that the expression of TSAs is directly dependent on Aire gene, 
this should be evident also throughout the development of thymic tissue. 
However, the thymic cell content and volume changes significantly during 
development leading to thymus decrease in size, weight and activity by the 
process of involution. Thymuses from different embryonic, neonatal, young or 
adult developmental stages were analyzed for the Aire and TSA expression by 
qRT-PCR (Figure 8). 
 
 
 
 
Figure 8. Aire and TSA expression during development. Thymuses were collected from 
normal WT mice at indicated time-points and the gene expression levels were analyzed 
by qRT-PCR. Aire expression, as well as the expression of Tff3, Ins2 and Spt1 genes 
reached their peak at day 11 (D11), Mup1 at 6 months (6m) after birth followed by a 
gradual decrease. Data are mean with S.E.M. of triplicate measurements of one out of 
two representative experiments. Dotted line corresponds to polynomial estimation. 
 
 
Very low Aire expression was detectable already at day E13.5, which signifi-
cantly increased at E15.5. Therefore, we propose that the start of Aire expres-
sion overlaps with the entry of the first wave of the hematopoietic cells into the 
thymus. In addition, we observed the highest expression level at postnatal D11 
and a gradual decrease thereafter until the very last time-point studied. Aire 
expression was, however, clearly present even in 12-month-old mice. Thus, the 
expression of TSAs closely followed the pattern of Aire reaching their peak at 
D11 and followed by a significant decrease, suggesting a role for Aire in TSA 
regulation. 
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5.1.3. The impact of Aire on over-expression of TSA 
Although Aire deficiency has been shown to reduce TSA mRNA levels, the 
ability of Aire to act as a single factor to up-regulate TSA expression has not 
been demonstrated. We asked whether the TSA expression is influenced by Aire 
in the conditions of Aire over-expression. Therefore, murine Aire gene was 
amplified from pcAire plasmid (made by Niko Sillanpää [72]) and cloned into 
pAdTrack-CMV plasmid, which was incorporated to adenoviral backbone 
plasmid pAdEasy-1. The recombinant plasmids were transfected into adeno-
virus packaging cell line HEK293 and recombinant Aire-expressing adeno-
viruses (AdAire-GFP; expresses green marker) (Figure 9A) were generated. The 
negative control (AdGFP) without insert was constructed similarly. Western 
blotting confirmed that transfected cells express Aire protein (Figure 9B) and it 
can be used as a tool to study Aire influence on the tissue-specific antigen 
expression. AdAire-GFP and negative control were transduced into primary 
stromal epithelial cells (which had lost Aire expression) and thymic medullary 
epithelial cell line TEC 1C6 and again TSA expression was studied by qRT-
PCR (Figure 9C, D). 
 
Figure 9. Over-expression of Aire induces TSA expression in primary thymic stromal 
cells and in thymic epithelial cell line. (A) Transduction of AdAire-GFP in HEK293 
resulted in production of Aire-GFP protein. (B) Aire detection in AdAire-GFP 
transduced HEK293 cell line by Western blot. (C) Monolayers of primary thymic 
stromal cells or (D) thymic medullary epithelial cell-line TEC 1C6 were infected with 
equal amounts of Ad-GFP or AdAire-GFP. The Aire influence on the expression of 
TSAs was assessed by qRT-PCR. Data are mean with S.E.M. of triplicate measure-
ments of one out of two representative experiments. 
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The addition of Aire increased the expression of Tff3, Ins2, Mup1 and Spt1 in 
monolayer culture of primary stromal cells and thymic medullary epithelial cell-
line TEC 1C6. Altogether, Aire is sufficient for TSA induction in thymic 
epithelial cells in conditions where thymic cell signals are absent. 
 
5.1.4. Ex vivo thymus culture and TSAs 
During the cultivation of  primary thymic monolayer culture we observed that 
the Aire expression fades after the disruption of 3-dimentional structure of the 
thymus. In addition, it has been shown that the 3D structure of thymus is needed 
for mTEC functions [155]. In order to gain insight into how the microenviron-
ment affects Aire and TSA expression, we cultivated 2-dimensional (mono-
layer) disaggregated (thymocyte depleted) culture and reaggregated thymic 
organ culture (RTOC; thymocytes added). Thymuses from E17,5 embryos of 
C57BL/6 mice were harvested and used as intact thymus (3D lobes), 
disaggregated (3D>2D) or reaggregated by mixing freshly purified thymocytes 
with disaggregated thymic stromal cells (Figure 10). 
 
 
 
Figure 10. Thymic microenvironment is required for Aire and TSA expression. Thy-
muses were used as intact thymus (3D lobes), dissaggregated (3D>2D) or reaggregated 
(RTOC) cultures. Disaggregation resulted in loss of expression of Aire and TSA, which 
was recovered after reaggregation (except Spt1). Data are mean with S.E.M. of triplicate 
measurements of one out of two representative experiments. 
 
The data show that the disruption of 3D structure of the thymus results in 
dramatical decrease of Aire and 4 TSAs, which was recovered by some extent 
by reaggregation suggesting a major role for the thymic microenvironment in 
Aire and TSA expression. 
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5.2. Aire infuences chemokine receptor CCR4 and  
CCR7 ligand expression (II) 
5.2.1. Expression of Aire and thymic chemokines  
in thymus and lymph nodes 
Since Aire has an ability to modulate TSA expression in thymic epithelial cells 
we were asked whether Aire can regulate the expression of thymic chemokines 
and influence the thymocyte migration. Since CCR4 and CCR7 have been 
shown to participate in cortico-medullary migration and negative selection, we 
choose to characterize the expression of 3 ligands for CCR4 (CCL5, CCL17 and 
CCL22), and 2 ligands for CCR7 (CCL19 and CCL21). We also selected CCR9 
ligand CCL25, which is a chemokine known to mediate the outward movement 
of DN thymocytes in thymus [11]. We analyzed the mRNA transcript levels of 
these 6 chemokines in thymuses and inguinal lymph nodes from mice with 
different genotypes such as WT and Aire KO (Figure 11). To detect expression 
of chemokines in the epithelial cell population only, the data was normalized to 
the expression level of keratin 8 (K8) mRNA, which is expressed selectively by 
thymic epithelial cells. 
 
 
 
Figure 11. Chemokine expression in thymus and inguinal lymph nodes. Thymi and 
inguinal lymph nodes were dissected from 6–8 weeks old wild type (WT) and Aire KO 
(KO) mice and analyzed by qRT-PCR. Data are mean with S.E.M. *, Student t-test, 
p<0.05; all other comparisons between WT and Aire KO are not significant, n=3–5. 
 
The expression of CCL5, CCL17, CCL22 (CCR4 ligands) and CCL19, CCL21 
(CCR7 ligands) was down-regulated in thymi from Aire KO mice, whereas the 
expression of the CCR9 ligand, CCL25, showed an increased expression in the 
Aire KO thymi. The expression of the chemokines in lymph nodes remained 
unchanged. 
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5.2.2. Thymic chemokines follow the expression of Aire during 
thymus development and involution 
As the TSAs followed Aire expression during thymus development (Figure 8) 
we asked whether thymic chemokines could also correlate the Aire expression. 
For this reason thymi from various mouse embryonic (E13,5-E17,5), neonatal 
(10 days), young (6 weeks) or adult developmental (6 months) stages were 
analyzed for Aire and thymic chemokine expression (Figure 12). 
 
Figure 12. Aire and chemokine expression during development. Thymuses were 
collected from normal WT mice at indicated embryonic (E) and post-natal (d-day, w-
week, m-month) time-points and the gene expression levels were assessed by qRT-PCR. 
Data are mean with S.E.M. of triplicate measurements of one out of two representative 
experiments. Line corresponds to polynomial estimation. 
 
 
The results demonstrate that the chemokines CCL5, CCL17, CCL21 and 
CCL25 were already expressed at the E13.5, though Aire showed little expres-
sion at this time-point. At the postnatal stage the expression level of most of the 
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thymic chemokines followed the pattern of Aire, with a peak at day 10 followed 
by gradually decrease in expression. The only exceptional chemokine was the 
CCR9 ligand, CCL25, whose expression started very high at E13.5, then 
decreased gradually at E17.5 time-point, and reached a second peak at post-
natal day 10, which decreased until 6 weeks of age. 
 
5.2.3. The impact of Aire over-expression  
on thymic chemokine expression 
Next, we asked whether Aire, as a single factor, can influence the thymic 
chemokine expression. And again, we used an adenoviral expression system 
(AdAire-GFP vs. Ad-GFP) for the overexpression of Aire. Infecting the TEC 
1C6 cells with AdAire-GFP or Ad-GFP control viruses resulted in a virtually 
equal infection rate as determined using FACS by evaluating the percentage of 
GFP positive cells at 48 hours (AIRE-GFP: 38.1±4.3% vs. ad-GFP: 42.8±2.8%; 
mean with S.E.M., n=3, data not shown). Infected cells were harvested for RNA 
purification and the expression was analyzed by qRT-PCR (Figure 13). 
 
 
 
Figure 13. Over-expression of Aire induces chemokine expression in thymic epithelial 
cells. Infected TEC 1C6 cells with AdAire-GFP (adAIRE) or Ad-GFP control (adGFP) 
viruses, C – uninfected TEC 1C6 cells. Data are mean with S.E.M. *, Student t-test, 
p<0.05; ns= not significant, n=3–5. 
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Infection of TEC 1C6 cells with AdAire-GFP resulted in a significant increase 
in the expression of CCL5, CCL22 and CCL19, whereas there was no change in 
the expression level of CCL17, CCL21 and CCL25 chemokines. Obtained 
results demonstrate that in the absence of signals provided by other cell-types 
present in thymus, Aire is sufficient to boost the expression of several thymic 
chemokines in TECs. 
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5.3. DNA methylation signatures of the AIRE promoter in 
thymic epithelial cells, thymomas and normal tissues (III) 
5.3.1. AIRE promoter methylation in thymus 
The presence of CpG island in AIRE promoter was suggested in 1997, when 
AIRE gene was identified [41]. In accordance with this, Murumägi et al. 
mapped the CpG island of AIRE gene, which starts from approximately 300 bp 
upstream of translation start site and encompasses the first exon (Figure 14). 
Additionally, it was demonstrated that the CpG island in AIRE gene is highly 
hypermethylated in several AIRE-negative cell lines [68]. Furthermore, AIRE 
expression was induced in methyltransferase DNMT1 and DNMT3b double-
deficient cell lines suggesting the regulation of AIRE gene expression via CpG 
methylation [69]. 
   
      
                           
Figure 14. Distribution of CpG positions within the AIRE promoter region. The 
positions of CpG dinucleotides in AIRE promoter CpG island (-295 to +65, positions 
relative to the atg of the AIRE gene) are indicated in bold and by numbers. The 
translation start site is indicated by the atg codon in boldface. Modified from [68]. 
 
 
 
First we analyzed the methylation of 47 CpG dinucleotide positions within the 
CpG island of the human AIRE gene in 5 normal thymus tissues (Figure 15) 
adjacent to thymomas by bisulfite sequencing. 
The analyzed 5 thymus samples showed highly variable methylation patterns 
from relatively moderate (20–60%) methylation across investigated positions to 
high (80–100%) methylation. In conclusion, these results confirm the presence 
of variable methylation pattern of the AIRE promoter on the level of normal 
thymus tissue. 
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Figure 15. AIRE promoter methylation pattern in normal thymus tissue across 47 CpG 
positions analyzed. Each bar represents the methylation of a single CpG motif. 
 
 
5.3.2. AIRE promoter methylation  
in human thymic epithelial cells 
The highly variable methylation pattern of the AIRE promoter in normal 
thymus tissues might be the result of differences in cell composition. Taking 
into account that thymocytes form the vast majority of all cell types in thymus, 
the observed results most likely reflect the thymocyte specific methylation 
pattern. Therefore, we purified epithelial cell subsets from human thymus tissue 
and measured AIRE expression in CD45+ cells, cTECs, immature MHC class 
IIlo and mature MHC class IIhi mTECs and normal thymus (Thy1) (Figure 16). 
 
Figure 16. Analysis of AIRE expression in normal 
thymus, sorted thymic epithelial cell and thymocyte 
populations. AIRE expression was analyzed by qRT-PCR 
in CD45+, cTEC, mTEC HLA-DRlo, mTEC HLA-DRhi 
cells.
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The obtained results confirm that the predominant cell population expressing AIRE 
in the thymus is terminally differentiated (mature) CD80hi/MHC class IIhi mTEC. 
We therefore asked further whether the CpG island within the human AIRE 
promoter is less methylated in the MHC class IIhi mTEC population when com-
pared to the other thymic epithelial subsets. To this end, we conducted the methy-
lation analysis of purified genomic DNA on respective populations (Figure 17). 
 
 
Figure 17. Analysis of the human AIRE promoter methylation pattern in sorted thymic 
cell populations. The methylation was analyzed in the following samples: (A) mTEC 
HLA-DRlo (population representing low AIRE expression, I–III) and (B) mTEC HLA-
DRhi (population representing high AIRE expression, I–III); (C) cTEC (I–III); (D) 
thymocytes (I–III). Each bar represents methylation of a single CpG position. 
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The methylation analysis of purified genomic DNA in three individual donors 
showed relatively uniform intraindividual methylation pattern between MHC 
class IIlo and MHC class IIhi mTEC subsets. Thymocyte population had 
relatively high methylation (60–80%) in positions analyzed. These results 
indicate that inspite of the strong induction of Aire expression during terminal 
differentiation of MHC class IIlo to MHC class IIhi mTECs is not associated with 
significant changes in the methylation of the AIRE promoter. 
 
5.3.3. AIRE promoter methylation in thymomas 
Thymomas are neoplasms of thymic epithelial cells and are classified into 
several subtypes according to the WHO classification [88], based on their 
morphology and the content of lymphocytes. AIRE expression is lost in 95% of 
thymomas and only 5% of thymomas, mainly representing a subset of the rare 
organoid type B1, express AIRE and their architecture largely resembles normal 
thymus [91]. To investigate, whether the absence of expression in thymomas 
might be the result of high methylation levels, we analyzed AIRE promoter 
methylation by bisulfite sequencing in 6 samples of type A (medullary type), 5 
samples of type B3 (cortical type) and 5 samples of type AB (mixed medullary 
and cortical type) thymomas (Figure 18). 
Current analysis demonstrated that all thymomas had highly diverse methy-
lation patterns with a clear prevalence of demethylation in the majority of 
sequenced positions. Based on the results, thymomas could be subdivided into 2 
groups: one group with complete methylation at single CpG positions (A, I and 
IV; B, III and IV; C, I and V), and a second group in which the promoter was 
highly demethylated (A, II, III and VI; B, II and V; C, II-IV). The only 
exception to this classification was thymoma IV from type A, which had a high 
degree of methylation (70–80%) in almost all CpG positions analyzed. We 
could not identify any methylation pattern in the AIRE promoter specific to 
types of thymomas. On the contrary, obtained data indicate that the thymoma 
samples despite of their type showed methylation patterns in the AIRE promoter 
that may reflect their clonal origin. 
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Figure 18. Human AIRE promoter methylation pattern in thymomas. (A) Type A (I–
VI), (B) type AB (I–V) and (C) type B3 (I–V) thymomas were analyzed for AIRE 
promoter methylation. Each bar under thymoma sample represents methylation map of a 
single CpG position. 
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5.3.4. AIRE mRNA expression and promoter methylation  
in peripheral tissues 
Previous results suggested a role for DNA methylation in the regulation of the 
AIRE gene in cell lines: treatment with DNA methyltransferase inhibiting 
reagent 5-aza-2ʼ-deoxycytidine upregulated the AIRE expression in different 
cell lines [68], and cells deficient in both DNMT1 and DNMT3b showed higher 
levels of AIRE expression than wild-type controls [69]. Hence, AIRE 
expression might be repressed in peripheral tissues due to hypermethylation in 
the AIRE promoter. We tested this hypothesis by correlating mRNA expression 
levels (Figure 19) with methylation in 14 normal tissues (Figure 20). 
AIRE expression in thymic cell populations such as CD45+, cTEC, mTEC 
HLA-DRlo, mTEC HLA-DRhi cells (Figure 19) was compared to the following 
samples: cerebellum, uterus, lung, kidney, myocardium, gray matter, spleen and 
liver. Expression analysis of peripheral tissue samples shows a lack of AIRE 
expression in most tissues compared to mature mTEC HLA-DRhi cells. 
 
 
 
Figure 19. AIRE mRNA expression level in thymus, thymic epithelial cell populations 
(CD45+, cTEC, mTEC HLA-DRlo, mTEC HLA-DRhi cells), peripheral tissues 
such as cerebellum, uterus, lung, kidney, myocardium, gray matter, spleen and liver 
from 4 donors (D1-D4). The expression was normalized to β-actin. 
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Figure 20. Analysis of the human AIRE promoter methylation in the peripheral tissues 
such as cerebellum, uterus, lung, kidney, myocardium, gray matter, spleen and liver 
from 4 donors (D1-D4). Each bar represents the methylation of a single CpG motif. 
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The AIRE promoter in tissues such as cerebellum, kidney, myocardium, gray 
matter and liver had a very low degree of methylation scattered across all 
positions studied. Uterus and lung samples showed a modest degree of 
methylation (10–40%) in the majority of analyzed positions. By contrast, the 
spleen had the greatest extent of methylation (about 60–70%) across the 
majority of CpG positions. In addition to tissue-specific patterns, the analysis 
demonstrated inter-individual differences in methylation pattern in several 
tissues. Alltogether, these data show that hypermethylation of the AIRE 
promoter does not account for the lack of AIRE expression in most peripheral 
tissues. 
5.3.5. AIRE expression correlates with  
permissive promoter histone marks 
Previous studies showed increased AIRE transcription upon treatment of human 
cell lines with trichostatin A [68] and increased H3K4me3 levels on the mouse 
Aire promoter during mTEC differentiation from CD80lo to CD80hi cells [119]. 
We investigated H3K4me3 and H3K27me3 chromatin modifications on human 
sorted cells. Due to limitations in the number of purified mTEC subsets from 
individual human thymic samples, we sorted for hemopoietic cells (i.e., CD45+, 
EpCAM-) and TECs (i.e., CD45-, EpCAM+). Firstly, AIRE expression levels 
were measured in EpCAM+ cells and CD45+ thymocytes (Figure 21, A). Se-
condly, we conducted Q2ChIP analysis of H3K4me3 and H3K27me3 
modifications on the AIRE promoter and gene region (covering promoter; 
intervening sequences and exons based on random selection) in EpCAM+ cells 
and CD45+ thymocytes (Figure 21, B). 
 
Figure 21. Chromatin modifications in the human AIRE promoter and gene. (A) AIRE 
expression levels were assessed in EpCAM+ cells and CD45+ thymocytes. (B) Q2ChIP 
analysis of the AIRE promoter and gene region (prom- promoter, IVS- intervening 
sequence, Ex- exon) in EpCAM+ cells and CD45+ thymocytes. The average values of 3 
independent experiments including SEM are shown. 
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AIRE expression is confined to mTEC population, which also express high 
levels of EpCAM. In order to detect histone modifications in the human AIRE 
gene in EpCAM+ TECs and CD45+ thymocytes, we applied the Q2ChIP method 
and used specific antibodies against H3K4me3 and H3K27me3, which mark 
transcriptionally active and silenced chromatin, respectively [129]. An antibody 
against the histone H3 C-terminus was used as an internal control. The AIRE 
gene promoter had a higher level of H3K4me3 in EpCAM+ cells than in CD45+ 
thymocytes. In EpCAM+ TECs, the H3K4me3 level was lower in intervening 
sequence 4 and exon 8 but slightly higher in intervening sequence 12 and exon 
14 towards the 3ʼend of the AIRE gene. The H3K27me3 levels in EpCAM+ 
TECs and CD45+ thymocytes were similarly low in the promoter region, further 
decreasing in the middle of the gene, and negligible in the intervening sequence 
12 at the 3ʼ end of the gene. The promoter of the housekeeping gene GAPDH 
served as a positive control. Thus, there is link between AIRE expression and 
H3K4me3 permissive histone modification on the AIRE promoter. 
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6. DISCUSSION 
The understanding of thymic expression of self-antigens started to evolve in the 
beginning of 1990s after the hypothesis presented by Boon and van Pel [156], 
suggesting that the thymus expresses many tissue-specific genes as genomic 
fragments. They proposed that promiscuous expression of peripheral proteins in 
the thymus allows immature thymocytes to become tolerant to self-proteins 
which they would encounter in peripheral sites within body. Consistent with 
this hypothesis Hanahan and colleagues demonstrated in 1997 that rare thymic 
medullary cells express pancreatic genes (i.e. insulin) [157] challenging general 
rules of cell-type specific gene expression. Although the significance of pro-
miscuous gene expression had been proposed long time ago, its role was 
strongly established with the discovery of how the lack of AIRE promotes auto-
immunity in human and mice. The establishment of purification protocol for 
thymic stromal cell populations [31] boosted investigation attempts towards 
characterization of peripheral tissue-specific antigens in thymus. The extra-
ordinary finding was that mTECs are specialized to express in random manner a 
highly diverse set of genes representing all tissues of the body and their 
expression is fully maintained in the involuting thymus of aging mice [31]. Our 
obtained results confirmed that the expression of four TSAs; trefoil factor 3 
(Tff3), insulin 2 (Ins2), salivary protein 1 (Spt1) and major urinary protein 1 
(Mup1), was limited to the mTEC population, i.e. the cell population of Aire 
expression. Unexpectedly, the expression level of all four TSAs in heterozygous 
mice thymus was around 10–20% (instead of expected 50% with 1 Aire gene 
copy) of the expression level in WT mice in both strains studied and the finding 
does not correlate with Aire gene copy number for unknown reason. It is 
possible that only one Aire copy is not sufficient for the functional activity of 
the gene product or that Aire has allele-specific expression. At the same time we 
detected  Aire allele dose-dependency of 2 copies for Tff3, Ins2, Spt1 and Mup1 
and confirmed that difference in mouse strains has no influence on Aire-
dependent TSAs. We observed that during development that the expression of 
TSAs closely followed the pattern of Aire reaching their peak at day 11 
followed by a significant decrease, suggesting a role for Aire in TSA regulation. 
Lack of Aire has been shown to reduce TSA mRNA levels [52, 83], but the 
ability of Aire to act as a sufficient factor to up-regulate TSA expression has not 
been demonstrated before our study. It is difficult to speculate how many copies 
of Aire inside the transduced cells are needed to promote TSA expression in 
monolayer cultures, which had previously lost the ability to express Aire and 
Aire-dependent TSAs. As overexpression of Aire in primary thymic stromal 
cells and thymic epithelial cell-line TEC 1C6 results in somewhat different ex-
pression level of TSAs, we can speculate that each culture has their own 
available combination of transcription factors needed for expression. 
The thymus provides specialized microenvironments that direct and support 
T cell differentiation and selection, which in turn influence the maturation of 
thymic epithelial compartment and the disruption of normal thymic architecture 
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changes the expression pattern and functionality of thymus [158]. The 
maturation of thymic epithelial stroma during the fetal period occurs 
independently of thymocyte-derived signals and is mainly regulated by thymic 
mesenchyme [159, 160], thymocytes deliver signaling molecules needed to 
maintain the normal thymic microenvironment. In this study, we show that the 
disruption of the three-dimensional thymic meshwork into two-dimensional 
culture results in rapid loss of Aire and TSA expression, whereas Aire as well as 
TSA expression was restored in reaggregated thymic organ culture. In the 
current case it could mean that interactions between mTECs and hematopoietic 
cells determine the scope of TSA expression. 
It also appears that the array of genes induced by Aire varies by cell type. 
The comparison of Aire activity, when ectopically expressed in various cell 
types, shows that Aire has the tendency for promoting TSA expression in a 
variety of cellular contexts, but a different set of TSAs can be activated in each 
case [100, 109, 161]. Interesting is the notion that although Aire induces the 
expression of thousands of TSAs in mature CD80hi mTECs, numerous TSAs are 
also expressed in conditions of Aire-deficiency and these Aire-induced and –
independent genes tend to cluster in the genome [83]. The results from the same 
study demonstrated that promiscuously expressed genes can be divided into 4 
subgroups: (a) genes that are expressed at similar levels in cTECs and mTECs 
and at much lower levels, if at all, in hematopoietic cells (e.g., PLP or thyro-
globulin); (b) genes that are only expressed in mTECs, irrespective of the 
maturation stage (e.g., CRP); (c) genes that are strongly induced in CD80hi 
mTECs dependent on Aire (e.g., insulin or casein α); and (d) genes that are 
induced in CD80hi in the absence of Aire (e.g., GAD67 or casein β). In the 
context of promiscuous gene expression the definition of tissue-specific (or 
tissue-restricted) genes are defined as genes that are expressed in fewer than 5 
of 45 tissues are defined as tissue-specific [83]. Aire-dependent TSAs seem to 
be transcribed differently than they are in the peripheral organ in which they are 
normally expressed [162]. One obvious difference between the thymic and 
peripheral tissue expression of TSAs is that the levels of TSA expression within 
mTECs are generally low when compared with the peripheral organ associated 
with a given TSA [31, 85]. This suggests that remarkably low level of antigen 
expression is sufficient for negative selection. The main mechanism by which 
Aire has been proposed to induce central tolerance is the promotion of the 
expression of peripheral tissue-specific genes in mTECs thus making them 
available for presentation. Current observations have suggested that there are 
two modes of presentations: firstly, known as antigen spreading, according to 
which TSAs are transferred to and cross-presented by thymic DC and secondly, 
self-antigen presentation by the mTEC themselves. Despite the thymic deletion 
of autoreactive T cells, a significant number of autoreactive T cells evade 
thymic deletion, which suggests that the process is incomplete. Therefore the 
mechanism of peripheral tolerance must exist to provide additional control to 
the process of thymic deletion. In our study, we detected the expression of both 
Aire and Ins2 antigen in inguinal lymph nodes, although the expression of Ins2 
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expression was not affected by the lack of Aire. After this it was published by 
other group that Aire in secondary lympoid organs is required for expression of 
several TSAs and these extrathymic Aire-expressing cells delete naive autore-
active T cells [161], which supports the immune tolerance by preventing the 
maturation of autoreactive T cells that escape thymic negative selection. Extra-
thymic Aire-expressing cells may play important role during aging and thymus 
involution shifting self-tolerance from thymus to periphery. 
In addition to the modulation of TSA expression, Aire influences the pro-
duction of the thymic chemokines involved in cortico-medullary migration and 
thus plays a role in intrathymic thymocyte migration and maturation. The 
cortico-medullary migration depends on the expression of two chemokine 
receptors, CCR4 and CCR7, and their corresponding ligands [11]. CCR4 and 
CCR7 are predominantly expressed on DP and SP CD4+ thymocytes [9, 10, 
163], while their ligands are produced predominantly in the thymic medulla [9, 
10, 164, 165]. Since the negative selection takes place in thymic medulla, the 
coordinated expression of CCR4 and CCR7 and their corresponding ligands is 
likely to direct the induction of central tolerance [11]. Moreover, array data 
from Aire KO mice suggests that in addition to down-regulation of TSAs, there 
is also an aberrant expression of a number of chemokines in the mTEC 
population [52, 83]. We currently showed that in Aire-deficient mice there is a 
down-regulation of the ligands for CCR4 and CCR7 (CCL5, CCL19 and 
CCL21), which are responsible for cortico-medullary migration. Whereas the 
expression of the chemokine, CCL25 [166], known to mediate the outward 
movement of DN thymocytes is elevated in the Aire KO mice, suggesting that 
the coordinated migration of thymocytes in Aire KO may be influenced at a 
different level of maturation. In this context we demonstrated that at the level of 
whole tissue, the majority of chemokines were not affected by Aire KO lymph 
nodes. Our results are in agreement with a report that stated that the number of 
Aire-target genes is different and more limited in the periphery [161] and also 
indicated a minor role for Aire in the regulation of peripheral chemokines. 
In concordance with Aire and TSA expression during development, the 
CCR4 and the CCR7 ligands followed the expression pattern of Aire by having 
the highest expression peak at day 10 and gradually declined thereafter. 
However, a clear signal for many chemokines at E13.5 was detected, before the 
obvious increase in Aire signal at day E15.5, which suggests that in early 
development, mechanisms other than Aire trigger the chemokine expression 
needed for migration of early thymocytes. We also showed that the over-
expression of Aire as a single factor induces the expression of the CCR4 ligands 
(CCL5 and CCL22), as well as the CCR7 ligand (CCL19). CCL17 and CCL21, 
although having clearly Aire-dependent expression, were not induced in other 
experimental settings, suggesting that optimal chemokine induction requires 
additional signals, maturation or cell-types. Likewise, the CCR9 ligand, CCL25, 
although negatively regulated in Aire-deficient situation, was not reduced by 
Aire overexpression, suggesting again an indirect mechanism behind this effect. 
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As Aire is predominantly expressed in the mature epithelial cells in thymus, 
we decided to investigate whether this tissue-specific expression is associated 
with CpG methylation signature in the promoter of the AIRE gene. Previous 
studies have demonstrated an induction of AIRE expression upon experimental 
global hypomethylation and increased AIRE expression levels in DNMT1 and 
DNMT3b double-deficient cell lines, which suggested that genomic methylation 
might be a critical mechanism for AIRE gene regulation [68, 69]. In mixed 
thymic cell populations we found partial methylation of the AIRE promoter with 
inter-individual differences in their methylation pattern and interestingly, this 
partial methylation was also present in purified thymic epithelial cell popu-
lations. One of the weaknesses of the experimental setup is the small sample 
size due to the limited availability of human thymic material. Despite this, our 
results support an earlier report about a high inter-individual variation in CpG 
methylation in eleven human somatic tissues [167]. We registered hypo-
methylation in AIRE-negative cTECs as well as in MHC class IIlo and MHC 
class IIhi mTECs in studied individuals. Regarding the strong induction of AIRE 
in MHC class IIhi mTECs upon terminal differentiation, our results argue 
against the hypothesis that DNA methylation plays an essential role in the regu-
lation of AIRE expression. This conclusion is supported by our results showing 
that the AIRE promoter is hypomethylated in most of the AIRE-negative 
extrathymic tissues (cerebellum, uterus, lung, kidney, myocardium, gray matter, 
spleen and liver) and in AIRE-negative thymomas. As extrathymic tissues 
originate from donors over 50 year of age (thymoma donor age unknown), it 
could be that hypomethylation increases with age. In addition, we could not 
identify methylation patterns in the AIRE promoter region specific to thymoma 
type, yet we could identify tumor-specific methylation patterns that may reflect 
their clonal origin. During investigation of histone modifications in the human 
AIRE gene we detected H3K4me3 modification, which is mark of transcriptio-
nally active chromatin, on AIRE promoter in EpCAM positive cells (enriched 
for Aire expressing mTECs). Taking into account that AIRE has high CpG 
motif content in investigated promoter region and it has tissue-specific expres-
sion pattern it is suggested that AIRE belongs to the subset of genes controlling 
developmental processes. Typically genes controlling developmental processes 
have low levels of CpG methylation and are enriched in H3K4me3 marks, 
which fits with AIRE recently described role in embryonic development and in 
mTEC maturation [76]. 
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7. CONCLUSIONS 
The following results are presented within the current thesis: 
1.  Current study characterized the expression of 4 TSAs in conditions where Aire 
was down- or upregulated: Aire had an allele dose-dependent effect on TSA 
expression in the thymuses of mice from two strains, C57BL/6J and Balb/c, 
but had no effect on TSA expression in the lymph nodes. Within the thymus, 
Aire and TSAs were both localized in the medulla and co-expressed during 
normal development and involution. Furthermore, over-expression of Aire 
gene resulted in an increase in TSA expression. The manipulation of in vitro 
organ-cultures demonstrated that thymic microenvironment plays a dominant 
role in Aire expression whereas TSAs follow the same expression pattern. 
2.  We showed that Aire has a dose-dependent effect on CCR4 and CCR7 ligand 
expression in the thymus. The CCR4 ligands are regulated by Aire in the 
CD80hi mTECs, whereas the CCR7 ligands are upregulated in adjacent cells. 
Overexpression of Aire induced the expression of CCL5, CCL22 and CCL19. 
3.  During the studies of Aire promoter methylation signatures in different cells 
and tissues we found that the AIRE promoter was hypomethylated in mTECs 
and cTECs but highly methylated in thymocytes. Furthermore, the AIRE 
promoter was hypomethylated in AIRE-negative thymic epithelial tumors 
(thymomas) and in peripheral tissues. Positive correlation was found in 
human TECs between AIRE expression and an active chromatin mark, 
histone H3K4me3 in the AIRE promoter. 
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SUMMARY IN ESTONIAN 
Autoimmuunregulaator:  
Tüümuse Geeniregulatsiooni ja Promootori  
Metülatsiooni Iseloomustamine 
Meie immuunsüsteem koosneb erinevatest spetsialiseerunud molekulidest, 
rakkudes, kudedest ja organitest, mis on arenenud kaitsmaks meid võõraste 
osakeste ja haiguste eest. Samaaegselt võõraste osakeste äratundmisega peab 
organism olema suuteline vahet tegema peremehe enda rakkude ja antigeenide 
vahel ja säilitama tolerantsuse enda komponentide suhtes. Terved indiviidid on 
tolerantsed nende endi antigeenide suhtes. Lümfotsüütide arengu käigus toimub 
juhuslik retseptorite kokkupanek, mis on võimelised ära tundma nii võõraid kui 
ka organismi enda komponente ja tolerantsus enda komponentide suhtes säilita-
takse hoides ära potentsiaalselt ohtlike organismi enda komponente äratundvate 
(ehk autoreaktiivsete) lümfotsüütide  küpsemise ja aktivatsiooni, vastasel juhul 
areneb autoimmuunsus. Tolerantsi peamiseks kujunemiskohaks on tüümus, kus 
küpsevatele lümfotsüütidele esitletakse ainult organismi enda antigeene, kuna 
võõrad antigeenid viiakse perifeersetesse lümfoidorganitesse nagu lümfisõlmed, 
põrn jne. Tüümuses leiab aset negatiivne selektsioon ehk autoreaktiivsete T-
rakkude selektiivne elimineerimine. Autoreaktiivsete T-rakkude elimineerimise 
eest vastutavad antigeene presenteerivad rakud, siia kuuluvad dentriitrakud ja 
tüümuse medullaarsed epiteelirakud (mTEC), kes esitlevad oma pinnal MHC 
molekuli-peptiidi komplekse T rakkude retseptoritele (TCR) T rakkude pinnal. 
Antud väitekirja kontekstis on eriti olulised antigeene presenteerivatest rak-
kudest just tüümuse medullaarsed epiteelirakud, millel on erakordne võime 
ekspresseerida suurel hulgal erinevaid geene, mis on omased teatud spetsiifilis-
tele perifeersetele kudedele. Immunoloogilise tolerantsuse tekkimiseks ja säili-
tamiseks on eriti oluline mTECides toimuv koespetsiifiliste geenide ekspres-
sioon, mida tuntakse ka avatud geeniekspressioonina, mis peaks tagama pideva 
autoreaktiivsete T-rakkude elimineerimise elu käigus. 
Medullaarsed epiteelirakud ekspresseerivad AIRE (Autoimmuunregulaator) 
geeni, mis suunab perifeersete koespetsiifiliste geenide avatud geeniekspres-
siooni. Hiljuti avastati, et mutatsioonid AIRE geenis toovad endaga kaasa 
haruldase mitmeid kudesid mõjutava autoimmuunhaiguse APECED (Auto-
immune Polyendocrinopathy Candidiasis Ectodermal Dystrophy), millega 
kaasneb immunoloogilise tolerantsuse kadumine mitmete endokriinorganite 
suhtes. Mutatsioonide tulemusena kaotab AIRE valk funktsionaalsuse koe-
spetsiifiliste geenide ekspresseerimisel ja autoreaktiivsete T rakkude eliminee-
rimine pole enam efektiivne ja selle tulemusena pääsevad autoreaktiivsed T 
rakud tüümusest perifeeriasse autoimmuunseid reaktsioone põhjustama. Käes-
olev dissertatsioon keskendub Aire geenist sõltuva koespetsiifiliste antigeenide 
ja kemokiinide ekspressiooni uurimisele, ja AIRE geeni promootori regulat-
siooni metülatsiooni sõltuvuse analüüsimisele. Koespetsiifiliste geenide töös 
uurisime, kas Aire lisamine või puudumine viib koespetsiifiliste geenide 
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ekspressiooni muutusteni ja kas see on limiteeritud tüümuse epiteeli rakkudega, 
ning kuidas muutub Aire ja koespetsiifiliste geenide ekspressioon tüümuse 
arengu käigus ja kas see on sõltuv tüümuse mikrokeskkonnast. Me leidsime, et 
koespetsiifiliste geenide ekspressioon on sõltuv Aire geeni koopiaarvust tüü-
muses kuid mitte perifeerses lümfisõlmes. Aire kui ka koespetsiifilised geenid 
ekspresseerusid tüümuse medullas ja neil oli sarnane avaldumismuster hiire 
tüümuse erinevatel arenguetappidel. Aire geeni üleekspresseerimise tingimustes 
tõusis ka koespetsiifiliste geenide avaldumine. Tüümuse struktuuri lõhkumise 
tulemusena langes kõigi uuritud geenide ekpressioon. Käesolevad tulemused 
näitavad, et Aire geenil on otsene roll koespetsiifiliste geenide ekspressioonil ja 
läbi Aire geeni on võimalik mõjutada tsentraalse tolerantsuse või autoimmuun-
suse tekkimist. 
Kuna tüümuse kemokiinid on olulised tüümusesse sisenevate tümotsüütide 
kortiko-medullaarsel migratsioonil, siis uurisime Aire geeni rolli tüümuse 
kemokiinide tootmises. Leidsime, et tüümuses Aire geeni puudumise tulemu-
sena langevad CCR4 ja CCR7 ligandide tasemed ning CCR4 ligandid on Aire 
poolt reguleeritud CD80hi mTEC rakkudes. Sarnaselt koespetsiifilistele anti-
geenidele jälgivad ka tüümuse kemokiinid Aire avaldumismustrit sünnijärgsel 
perioodil. Aire geeni üleekspresseerimise tingimustes tõusis CCL5, CCL22 ja 
CCL19 kemokiinide tase. Antud leidude puhul on tegemist Aire uudse rolliga 
tsentraalse tolerantsuse kujunemise kontekstis. 
AIRE promooteri metülatsiooni uurides leidsime, et AIRE promooter oli 
hüpometüleeritud mTECides ja cTECides ning CpG metülatsiooni tase tõusis 
AIRE negatiivsetes tümotsüütides. Samas oli AIRE promooter hüpometülee-
ritud Aire negatiivsetes tüümuse kasvajates ja perifeersetes kudedes. Ning leid-
sime positiivse korrelatsiooni AIRE ekspressiooni ja AIRE promooteril asuva 
aktiivse kromatiini märgise H3K4me3 vahel. 
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